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The main aim of this study is to find out the mechanisms of Chinese herbs, which 
are claimed to possess anti-tumor effects in gastric cancer on how it work on 
different stages of colon cancer cells and whether cell death induction and 
immunomodulation are involved.
In this preliminary study, the four human colonic cells were shown to have 
varying degree of cell death as well as cell cycle arrest when treated with 
combined herbs. Cells of different stages of colon cancer showed varying 
responses to the various herbs when tested individually. Increased cell death was 
observed only in some individual herbal treatment.
Synergistic effect was observed in human colonic carcinoma cells HCT-116 when 
treated with a combination of Radix actinidiae chinesis and Herba sarandrae
while combinatorial effect exerted by the individual herbs on human colonic 
adenocarcinoma cells CaCO-2 correspond to the amount of cell death observed 
when treated with combined herbs. Normal human colonic cells CRL-1790 and 
human colonic adenocarcinoma cells HT-29 were shown to have little or no effect 
when treated with individual herbs which could possibly indicate that the herbs 




The increased cell death measured in both combined and individual herbs-treated 
human colonic cells were caused by apoptosis as indicated by DNA fragmentation 
using the DNA laddering assay. Cytotoxicity assay used in the measurement of 
lactate dehydrogenase indicative of necrosis was used. A drop in lactate 
dehydrogenase were measured which indicates that the herbal treatment may not 
have caused necrosis in cancer cells. Thus the increased cell death was caused by 
apoptosis and targeting apoptosis has always been a promising strategy for cancer 
drug discovery.
ELISA was performed to determine the immunomodulatory effect of the herbs on 
the colonic cells. Cells of difference phases of colon cancer showed differing 
responses to the various herbs tested. A general trend of anti-inflammatory 
cytokine IL-4 and IL-10 was shown to be up-regulated with a corresponding 
down-regulation in level of IL-8 and TGF-β1. Cytokine results correspond to that 
of the cytotoxicity assay where the herbs showed a general trend of lowering 
necrosis.
This preliminary study gives an indication of the potential of the therapeutic 
effects exerted by the herbs. More prominent effects of individual herb treatment
were seen in colon cancer of a later stage, which could prove to be beneficial for 





Chinese herbal medicine has been used in China and other Asian countries for 
thousands of years to treat a wide range of disorders from skin to internal diseases 
of the body. With its long history in clinical usage, Chinese medicine has 
established an important role in health care. Herbal medicine is used to treat mild 
disorders such as the common cold or flu to more serious diseases including heart 
disease, hepatitis and cancer. Usages of Chinese herbs have gain popularity 
significantly over the past several years as adjunctive therapy for both acute and 
chronic medical problems. The increasing popularity of Chinese medicine, more 
recently in the Western countries, is due to the belief that Chinese herbal medicine 
is milder and safer.
There are approximately 500 different Chinese herbs in the Chinese Materia 
Medica, the Chinese medicine pharmacological reference book (Bensky 1993). 
Different parts of the plants can be used as herbal medicine, including the leaves, 
roots, stems, flowers and seeds to perform different functions. Chinese medicinal 
herbs are medicines from nature and are generally mild in actions, lacking many 
side effects at the normal dosage (Badisa 2003). Chinese herbs are relatively 
inexpensive and safer as compared to that of the synthetic drugs. 
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Herbs are rich in both biologically active and inert substances with scavenging, 
detoxication as well as anti-oxidant properties. Herbs are commonly being 
prescribed as a mixed medicinal formula and are therefore multifunctional in 
activities as compared to synthetic drugs which are mainly made up of a single 
biologically active ingredient. Chinese herbs are rarely used individually as a 
combination of herbs helps to reduce toxicity of herbs as well as to enhance 
beneficial effects of other herbs.
Numerous clinical records have showed that some Chinese medicinal herbs have 
anticancer effects and do help to improve the living quality of patients suffering 
from cancer. Clinical trials have also demonstrated that some Chinese medicinal 
herbs and formulas could help in the reduction of side effects induced by 
chemotherapy and radiotherapy, lowering the relapse and metastasis rates. Thus, 
there is an increased interest in the mechanisms of anticancer effects of the 
Chinese medicinal herbs as many commercially available drugs such as taxol, 
aspirin and digoxin were also obtained from plant sources (Schafer 2002). 
Colon cancer is now the leading cause of death in the world. The cause of 
colorectal cancer is widely accepted to be due to the accumulation of genetic 
mutation in genes controlling cell division, apoptosis and DNA repair (Kinzler 
1996). Many epidemiological studies have now indicated that the processes of 
carcinogenesis and tumorigenesis are mainly induced by dietary and 
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environmental factors (Willet 1989). 
Besides being complementary medicinal drugs, Chinese herbs had been widely 
used in the prevention as well as treatment of colon cancer. Conventional cancer 
therapies have proven to have low efficiency in cancer treatment. On the other 
hand, these alternative medicines are increasingly being used in treatments and 
therefore major interests have arisen on how these herbs work in disease cure and 
prevention. Colon cancer is one of the top ranking cancer in the world and second 
most common cancer in Singapore and it is of interest to find out the mechanism 
by which the Chinese medicine works on colon cancer. The Chinese medicine was 
used in the treatment of colon cancer and it is of our interest to find out the
application of the Chinese medicine: (1) If the Chinese medicine induced cell 
death to a greater degree in cancer cells than normal cells, it might be proven to be 
effective in the treatment of colon cancer, (2) If the Chinese medicine does not 
have any effect on the cancer cells and shows adverse effects on the normal colon 
cells, such treatment should be critically considered. Thus, the main aim of this 
study is to find out the involvement of cell death induction and 
immunomodulation in human colonic cancer cells when treated with Chinese 





Cancer is formed when cells in a part of the body start to grow out of control 
whereby disorders occur in the normal processes of cell division controlled by the 
genetic material of the cell. Cancer may be caused by incorrect diet, genetic 
predisposition as well as environmental factors. About 35% of all cancers 
worldwide are caused by an incorrect diet and in the case of colon cancer, diet 
alone may account for 80% of the cases (Doll 1981). There is increasing evidence 
that diet-rich in vegetables, fruits and grains can reduce the risk of several cancers, 
including colon cancer (Thun 1992; Ames 1995).
Transformation of normal cells into cancerous cells requires processes through 
many stages over a number of years or even decades, including initiation, 
promotion, and progression. The first stage would involve an interaction between 
the cancer-producing substances and the DNA of tissue cells. Cells in this stage 
may remain dormant for years where the individual may only be at risk for 
developing cancer at a later stage. During the second stage, a change in diet and 
lifestyle may have a beneficial effect such that the individual may not develop 
cancer during his or her lifetime. The third and final stage would involve the 




Development of colon cancer is a multistage genetic alteration that occurs due to 
accumulation of mutations including the activation of dominant oncogenes and 
inactivation of tumor suppressor genes thereby giving growth advantages to the 
altered cells leading to cancer initiation (Bishop 1991; Vogelstein 1993; Kinzler 
1996). Humans and rodent studies have also demonstrated that tumorigenesis is a 
complex multi-step progressive disruption of homeostatic mechanisms controlling 
intestinal epithelial cell proliferation, differentiation and apoptosis (Kinzler 1996). 
Among the different neoplasms, colorectal cancer is one of the most frequent in 
human and is also the best characterized for genetic progression. Colorectal cancer 
progresses through a series of clinical and histopathological stages ranging from 
single crypt lesion through small benign tumors (adenomatous polyps) and 
ultimately to malignant cancers (carcinomas) (Vogelstein 2001). The number of 
genetic defects described as playing a potential role during the development and 
progression of colorectal cancer has been increasing steadily in recent years (Ilyas 
1999; Chung 2000). Early diagnosis of colorectal cancer by colonoscopy and 
detection of mutations in fecal DNA can help to reduce the rate of occurrence of 
colorectal cancer (Sidransky 1992; Traverso 2002).  
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2.1.2 Characteristics of colon cancer
Colon cancer is characterized by a change in bowel habits, with persistent diarrhea 
or constipation or a change in the frequency of stools. Stools mixed with blood 
and persistent abdominal pains are also signs of colon cancer.
2.1.3 Risk factors
The etiology of colon cancer is complex and involves both genetic and 
environmental factors. Carcinogens found in the diet triggering the initial stage of 
colon cancer include mycotoxin in particular and aflatoxins, nitrosamines, 
oxidized fats and cooking oils, alcohol and preservatives. Another potential 
dietary risk factor of colon cancer is the high consumption of meat through the 
formation of heterocyclic amines, which are formed during cooking. Other known 
risk factors include individuals with a family history of colon cancer, age, alcohol 
and fat intake. Individuals with parents, siblings or relatives suffering from colon 
cancer have a higher risk of genetic predisposition to suffer from colon cancer. 
Thirty percent of the population is considered to be at an increased risk because of 
family history of colon cancer, personal history of polyps, inflammatory bowel 
disease, or familial polyposis syndromes.
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2.1.4 Frequency of occurrence
In today’s world, millions of people are suffering from cancers, with colon cancer 
being one of the leading causes of death worldwide (Statistics from the American 
Cancer Society 2002; Silverberg 1985). Frequency of cancer diagnosed increases 
with age (as shown in Figure 2.1) due to the multiple mutations acquire over time 
which could be related to the number of rate-limiting steps involved in the 
formation of a malignant tumor. The rate of colorectal incidence has been on the 
rise over the years in both males and females. Statistics have shown that colorectal 
cancer in the western countries have an incidence that can be more than ten times
that of Asia, Africa and South America (Silverberg 1985). 
Literature Review
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Figure 2.1. Incidence rate of colorectal cancer with age. Source: Surveillance, 




2.1.5 Development of colon cancer
Figure 2.2. Genes involved in the progression of colon cancer. Diagram taken 
from Rafter J, Govers M, Martel P, Pannemans D, Pool-Zobel B, Rechkemmer G, 
Rowland I, Tuijtelaars S, van Loo J. (2004) PASSCLAIM – Diet-related cancer. 
European Journal of Nutrition 43: II47-II84
Carcinogenesis for most cancers is a process developing for decades (10-30 
years). Most colon cancer develops from adenomatous (benign) polyps and an 
average of 10 years is required for a 1-cm polyp to develop into a malignancy. 
Several stages in the process can be discriminated, e.g. initiation, promotion and 
progression. At various stages of cancer development, characteristic molecular 
and cellular changes occur as shown in Figure 2.2. Many of these different stages 
can be modulated by dietary factors (food components and ingredients) either by 
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direct interaction with gene expression or through the modulation of key enzyme 
activities involved in cell proliferation and differentiation, respectively.
2.1.6 Genetic events involved in colon cancer
Colon cancer is one of the best-characterized epithelial tumors and is a significant 
cause of morbidity and mortality worldwide. It develops as a result of the 
pathologic transformation of normal colonic epithelium to an adenomatous polyp 
and ultimately an invasive cancer. A defining characteristic of colorectal cancer is 
its genetic instability. Mutations in 2 classes of genes, tumor-suppressor genes and 
proto-oncogenes were thought to impart a proliferative advantage to cells and 
contribute to development of the malignant phenotype. The key initiating events 
that occur in both familial and sporadic colon cancer are genetic mutations in the 
adenomatous polyposis coli (APC) tumor suppressor gene. It was shown by Fodde 
et al (2001) that the primary transforming event in intestinal epithelium involves 
the loss of β-catenin regulation, which can occur either through truncation of APC 
or through the occurrence of oncogenic β-catenin mutations that render it resistant 
to proteolytic degradation. Loss of APC function or gain of β-catenin function 
leads to clonal expansion of the mutated epithelial cell, giving rise to a small 
adenoma (Su 1992). Genetic disruption of the APC pathway was altered in 
approximately 95% of colorectal cancer (Powell 1992). Mutation of the APC gene 
occurs due to the loss of heterozygosity on 5q, which is the locus of the APC gene. 




Aberrant crypt foci (ACF) is one of the earliest lesions observed in colorectal 
cancer and ACF is frequently known to be the precursor to the adenomatous 
polyps, which is the presursor lesion for colon carcinoma (Jen 1994; Otori 1998). 
p53 gene is involved in the transition from adenoma to high-grade dysplasia, 
which allows for malignant transformation to take place (Hanahan 2000). 
Mutation of the tumor-suppressor gene p53 on chromosome 17p appears to be a 
late phenomenon in colorectal carcinogenesis. This mutation may allow the 
growing tumor with multiple genetic alterations to evade cell cycle arrest and 
apoptosis (Gryfe 1997). p53 is a particularly important link between nuclear 
damage and mitochondria, and this link can be inactivated in cancer at multiple 
levels (Slee 2004). 
It was reported that 30-45% of the sporadic colon tumors occur when truncating 
mutations (nonsense and frame shift mutations) occur within the mutation cluster 




2.1.7 Role of apoptosis in colon cancer
The balance between proliferation and apoptosis is critical to the maintenance of 
steady-state number for cell populations in the colon (Hall 1994). In general, 
dysregulation of this delicate balance can disrupt homeostasis, resulting in clonal 
expansion of the affected cells. When apoptosis is defective, attenuated or 
inactivated, an increase in the rate of colonic cell proliferation would lead to an 
increase risk of DNA damage (Bedi 1995). There is an accumulation of evidence 
that the process of transformation of colonic epithelium to carcinoma is associated 
with progressive inhibition of apoptosis (Bedi 1995; Chang 1997; Hall 1994; 
Wright 1994).
2.1.8 Current treatment of colon cancer
Colorectal cancer is one of the most common cancers worldwide. Surgery with the 
removal of the cancer and its surrounding fat and lymph glands is the only 
curative option for patients with colorectal cancer. Surgery is normally followed 
by chemotherapy, immunotherapy or radiotherapy to prolong survival and reduce 
the risk of recurrence. However, advanced colon carcinoma can be very refractive 
to the standard therapies (Weisburger 1996). 
2.2 Intestinal epithelial linings
The epithelial cells of our intestine constitute the first-line of protection from the 
external environment. The epithelial linings help to protect the underlying 
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biological compartments from both the commensal flora that reside within the 
intestinal lumen as well as uninvited pathogens. The epithelial lining of the adult 
intestine is a dynamic system where processes such as cell proliferation, 
differentiation, migration and apoptosis occur all at the same time. The short life 
span and constant renewal of the cells of the intestinal epithelial lining also 
functions as a defense mechanism. Thus, if an intestinal cell becomes infected or 
damaged, the cell would normally undergo apoptosis within a few days and is then 
excreted out of the body as feces (Falk 1998).
2.3 Apoptosis
Death pathways of cells consisting of apoptosis, autophagy and necrosis are 
classified by morphological criteria (Jaattela 2004). Apoptosis is a cell suicide 
mechanism that enables multi-cellular organisms to regulate their cell number in 
tissues and to eliminate unneeded or ageing cells. Apoptosis can be defined as 
'gene-directed cellular self-destruction'; it is also referred to as 'programmed cell 
death (PCD)'. PCD is a normal physiological process where cells are programmed 
to die at a particular point, e.g. during embryonic development as well as in the 
maintenance of tissue homeostasis. It was originally described by Kerr at al (1972) 
that there are two main forms of cell death, which may occur in the absence of 
pathological manifestations, namely necrosis and apoptosis. 
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Apoptosis can be distinguished both morphologically and functionally from 
necrosis, which is a pathological cell death resulting from gross insults such as 
prolonged ischaemia that affects many adjacent cells simultaneously. In contrast, 
apoptosis typically occurs in single cell. Apoptosis is normally initiated by 
endogenous stimuli, such as the absence of vital growth factors or hormones and 
the action of cytokines, like tumor necrosis factor α (TNF-α) or Fas ligand (Kerr 
1994; Baker 1996).
2.3.1 Characteristics of apoptosis
Apoptosis is the best-defined cell death programme counteracting tumor growth. It 
is characterized by biochemical changes, which include the externalization of 
phosphatidylserine and other alterations that promote the recognition by 
phagocytes. Activation of a specific family of cysteine proteases, the caspases 
defines a cellular response leading to apoptosis (Earnshaw 1999). Certain 
caspase-mediated morphological features characterized the apoptotic program 
which includes changes in the plasma membrane such as loss of membrane 
asymmetry, active membrane blebbing and attachment, a condensation of the 
cytoplasm and nucleus, cell shrinkage and internucleosomal cleavage of DNA. In 
the final stages, the dying cells become fragmented into “apoptotic bodies” which 
are rapidly engulfed by neighboring cells and phagocytic cells without eliciting 




2.3.2 Pathways involved in apoptosis
Apoptosis involves a series of cellular death sensors and effectors that initiate the 
death pathway. Apoptotic signals have been reported to differ among different cell 
types and can be divided into two components – those that involve the 
mitochondria (intrinsic pathway) or those that signal through death receptors 
(extrinsic pathway). 
In the death receptor pathway, ligands such as tumor-necrosis factor, FAS ligand 
or TNF-related apoptosis-inducing ligand (TRAIL) interact with their respective 
death receptors. Death effector domain (DED) is predominantly found in 
components of the death-inducing signaling complex (DISC). In 
caspase-dependent apoptosis, a number of proteins contain such homotypic 
protein interaction domains. Four such domains that mediate apoptotic signaling 
include the DED, the death domain (DD), the caspase activation and recruitment 
domain (CARD) and the pyrin domain have previously been described 
(Fairbrother 2001). Interactions with the ligands ultimately lead to the recruitment 
of the FAS-associated death domain and the activation of DED-containing 
caspase-8 and caspase-10. Large amounts of active caspase-8 are produced at the 
DISC, and these large amounts of caspase-8 can directly cleave effector caspases 
bypassing the mitochondrial pathway (Nagata 1997). Activated initiator caspases 
(caspase-8 and caspase-10) are cleaved and thereby induce apoptosis either by 
direct activation of effector caspase-3, caspase-6 and caspase-7 which are 
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responsible for the execution of the cell death program or via a 
Bax/Bak-dependent mitochondrial membrane permeabilisation (MMP) triggered 
by caspase-8-mediated cleavage of Bid (Luo 1998; Scaffidi 1998) 
However, in the mitochondrial-mediated pathway, cells such as hepatocytes 
require the involvement of a mitochondrial amplification pathway to achieve a 
sufficient degree of activation of the effector caspases, as the caspase-8 produced 
by the DISC in these cells is insufficient to directly cleave the effector caspases. 
But the small amount of caspase-8 present is sufficient to cleave the protein Bid, a 
proapoptotic member of the Bcl-2 family, which would in turn, lead to the 
apoptogenic activity of the mitochondria causing mitochondrial dysfunction (Li 
1998; Luo 1998). Truncated Bid when transmigrated to the mitochondria induces 
cytochrome c release from the intermembrane space of the mitochondria into the 
cytosol. Cytochrome c would then bind to apoptotic protease-activating factor-1 
together with dATP (2’-deoxyadenosine 5’-triphosphate) forming a multimeric 
complex that result in the activation of caspase-9, which would activate 
downstream effector caspase (Budihardjo 1999). Death signals are typically 
focused on the mitochondria where release of cytochrome c catalyses apoptosis 
induction. Caspases finally transmit the death signal by specifically cleaving vital 
proteins of the nuclear lamina, such as poly (ADP-ribose) polymerase (PARP) and 
cell cytoskeleton, which results in cell disassembly.
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2.3.3 Role of caspases in apoptosis
One of the earliest and most consistently observed features of apoptosis is the 
induction of a series of cytosolic proteases, the caspases. Caspases are cysteine 
proteases that are responsible for the dismantling of the cell during apoptosis. 
These proteins are expressed as zymogens and become active proteases only after 
cleavage at specific sites within the molecule (Stegh 2001). The structure of 
caspases is generally conserved and contains a pro-domain at the N-terminus, 
consisting of a large and a small subunit. The active caspase molecule is 
comprised of a heterotetramer of two of each of the large and small subunits. 
Caspases are generally divided into two groups based in their general role in 
apoptosis. Effector caspases which induce the bulk of the morphological changes 
that occur during apoptosis and the initiator caspases that is generally responsible 
for the activation of the effector caspases. 
Active caspases cleave numerous intracellular proteins and contribute to 
characteristic apoptotic morphology. Caspase-8 cleaves and activates caspase-3 
and other downstream caspases, which results in a proteolytic cascade that gives 
rise to various morphological changes as previously described in section 2.4.1. 
Caspase-3, in particular, plays a central role in this process. Another of the earlier 
markers of apoptosis is the loss of membrane asymmetry, including a 
redistribution of phosphotidylserine to the outer leaflet of the plasma membrane 




2.3.4 Non-caspase directed apoptosis
Accumulating data now show that apoptosis can also occur in the absence of 
caspases where non-caspase proteases and other death effectors function as 
executioners emerged. (Ferri 2001; Leist 2001; Lockshin 2002). Experiments 
using cancer cells with defective apoptosis machinery have shown that most 
caspase-activating stimuli, including oncogenes, p53, DNA-damaging drugs, 
proapoptotic Bcl-2 family members, cytotoxic lymphocytes and in some cases 
even death receptors, do not require known caspases for apoptosis to occur (Leist 
2001; Mathiasen 2002)
2.3.5 Dysregulation of apoptosis
Apoptosis is a natural process for removing unwanted cells such as those with 
potentially harmful mutations, aberrant substratum attachment, or alterations in 
cell cycle control. Deregulation of apoptosis can disrupt the delicate balance 
between cell proliferation and cell death leading to diseases such as cancer, 
autoimmunity, AIDS and neurological disorders (Danial 2004; Reed 1994; Hanada 
1995; Thompson 1995). In many cancers, pro-apoptotic proteins were shown to 
have inactivating mutations or upregulation in anti-apoptotic protein expression, 
leading to unchecked growth of the tumor and the inability to respond to cellular 
stress, harmful mutations and DNA damage (Hanahan 2000). It was demonstrated 
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by Elder (1996) that transformation of the colorectal epithelium into adenomas 
and carcinomas is closely associated with a progressive inhibition of apoptosis. 
2.4 Necrosis
Necrosis, which typically occurs as a result of cell injury or exposure to cytotoxic 
chemicals, is distinct from apoptosis in terms of both morphological and 
biochemical characteristics.
Necrotic cell death would begin with swelling of the cell and mitochondrial 
contents, followed by the rupturing of the cell membrane. In contrast to apoptosis, 
necrosis would trigger an inflammatory reaction in the surrounding tissue as a 
result of the release of cytoplasmic contents, many of which are proteolytic 
enzymes. 
2.5 Inflammation 
Inflammation is a complex response, at both the cellular and tissue level, to a 
variety of stimuli, including heat, trauma, viral or bacterial infections, and 
endotoxemia, and is very often a consequence of immune system activity and 
wound healing (Hart 2002; Ley 2001; Elenkov 2002). A persistent state of 
inflammation is thought to produce chronic damages leading to atherosclerosis, 
neurodegenerative disorders and certain types of cancer (Ludewig 2002; Perry 
1998; Shacter 2002). Inflammation was also shown to favor the formation of 
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tumorigenesis by stimulating the formation of angiogenesis, DNA damage as well 
as chronically stimulating cell proliferation (Jackson 1997; Phoa 2002; Jaiswal 
2000; Moore 2002; Nakajima 1997). 
Both animal models and epidemiological observations have suggested that a 
continuous inflammatory condition predisposes to colorectal cancer (CRC). 
Proinflammatory genes have also been shown to be important for the maintenance 
and progression of colorectal cancer (Eberhart 1994). Precursor lesions of 
colorectal cancer regardless of adenomas or polyps often have inflammatory 
histological features (Rhodes 2002; Higaki 1999). In normal colon and rectum, the 
mucosa is kept in a continuous state of low-grade inflammation by the intestinal 
bacterial flora which stimulates the release of proinflammatory cytokines by the 
immune cells (Rhodes 2002; Qureshi 1999). 
2.5.1 Role of cytokines in immunoregulation
T helper cell-dependent immune responses are generally divided into two cell 
types, T helper type 1 (Th1) and Th2 cells based on the type of cytokine produced. 
In Th1-type responses, antigen presenting cells would release interleukin-12 
(IL-12), which would in turn induces the differentiation of CD4+ Th1 cells to 
produce IL-2 and interferon (IFN)-γ. Th1 type cells are responsible for 
cell-mediated immune responses. However, when uncontrolled, Th1 responses can 
result in chronic inflammatory diseases, such as diabetes, arthritis, and multiple 
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sclerosis. Thus, it is critical that development of Th1-type cells is under control to 
prevent the development of some chronic inflammatory diseases. Th2-type 
responses are characterized by the development of CD4+ Th2 cells, which secrete 
IL-4, IL-6, IL-10, and IL-13 and play an important role in the humoral immune 
response leading to antibody production (O’Garra 1994; Abbas 1996). Some 
Th2-type cytokines, especially IL-4 and IL-10, are known to suppress the 
development of Th1 cells (O’Garra 1997; Racke 1994; Rocken 1996).  
2.5.2 Interleukin 4 (IL-4)
IL-4, a Th2 type cytokine was reported to inhibit carcinoma cell growth and 
promote the expression of differentiation-associated products by normal and 
malignant epithelial cells (Brown 1997). 
2.5.2.1 IL-4 receptor
The IL-4 receptor (IL-4R) consists of the cytokine-specific IL-4R α-chain and the 
common γ-chain shared by IL-2, IL-7, IL-9, and IL-15 receptors which is 
expressed on many cell types, including T cells, B cells, monocytes, and 
nonhemopoietic cells as well as intestinal epithelial cells (Chomarat 1998; 
Leonard 1996; Reinecker 1995). It was previously shown that functional IL-4R is 
expressed in a wide range of human cancer cells such as melanoma, renal cell, 
gastric, lung, breast and colon carcinomas (Hoon 1991a; Hoon 1991b; Obiri  
1993; Morisaki 1992; Toi 1992; Tungekar 1991; Kaklamanis 1992). Kaklamanis 
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(1992) had also shown that IL-4R is expressed by both normal intestinal mucosa 
and majority of colorectal tumors. IL-4 is predominantly secreted by stimulated 
CD4+ T cells, mast cells, and basophils and plays an interesting role in the 
regulation of non-hemopoietic tumor growth (Brown 1987; Hoon 1996; Howard 
1982; Paul 1987).
2.5.2.2 Functions of IL-4
IL-4 has pleiotropic effects on a wide variety of cell types of hematopoietic and 
non-hematopoietic origin (Paul 1991; Paul 1994). IL-4 plays a significant role in 
cell growth control and regulation of the immune system by inducing proliferation 
of T cells and promotes growth of B cells co-stimulated by anti-IgM (Brown 1988; 
Howard 1982; Kaplan 1998; Miller 1990; Spits 1987). In contrast to its growth 
stimulatory effect on lymphocytes, IL-4 significantly inhibits proliferation of 
many other kinds of cells, including those derived from human melanoma, colon, 
renal, and breast carcinoma (Hollingsworth 1996; Hoon 1991b; Lahm 1994; 
Morisaki 1992; Tepper 1989; Toi 1992; Topp 1995; Uchiyama 1996). IL-4 plays a 
central role in immunoregulation by polarizing the immune system towards 
Th2-type responses through the promotion of B cell differentiation, IgE and IgG1 
isotype switching and down-regulation of Th1-type responses (Brown 1997). It 
has been shown that an increase of IL4 serum levels in all activation condition is 
indicative of the passage from normal mucosa to adenoma (Contasta 2003).
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2.5.2.3 Implications of the presence of IL-4
Increased expression of IL-4 by approximately 20% had been shown to be 
associated with improved survival where the 5-year survival rates increase from 
50% to 87%. IL-4 is commonly expressed by colon carcinoma tumor infiltrating 
lymphocytes and is associated with improved survival (Barth 1996). IL-4 was 
reported to promote the expression of the functional or differentiation-associated 
epithelial proteins. Thus, IL-4 induces differentiation at the expense of 
proliferation in colorectal carcinoma cells (Al-Tubuly 1997). 
2.5.3 Interleukin 10 (IL-10)
IL-10 is a pleiotropic cytokine involved in both cell-mediated and humoral 
immune responses (Melgar 2003). IL-10 is a Th2 cytokine that suppresses Th1 
cell-mediated immune responses and a regulatory molecule for angiogenesis in 
various cancers (Moore KW 1993). 
2.5.3.1 IL-10 receptor
The IL-10 receptor complex is made up of two ligand-binding chains and two 
accessory chains (Kotenko 1997; Moore KW 2001; Walter 2002). IL-10 when 
bound to the IL-10 receptor complex results in kinase phosphorylation (Finbloom 
1995). Immunosuppressive cytokine IL-10 is produced by a variety of cells 
including T cells, B cells, antigen-presenting cells immunocompetent cells, 
neuroblastoma as well as carcinoma of breast, pancreas, kidney, and colon. (Gastl 
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1993; Kim 1995) The colon and ileum display IL-10 in the epithelium, lamina 
propria and submucosa, while jejunum display IL-10 only in the epithelium 
(Autschbach 1998; Beckett 1996).
2.5.3.2 Functions of IL-10
IL-10, a Th2 type cytokine, is known to suppress the functions of both T 
lymphocytes and macrophages, working as a general dampener of the immune and 
inflammatory responses thus facilitating the suppression of antitumor immunity. 
IL-10 was previously demonstrated to down-regulate cell-mediated immunity and 
increases host susceptibility to bacterial and parasitic infections. IL-10 can also 
inhibit the functions of antigen-presenting cells, including down-regulation of 
co-stimulatory molecules, resulting in suppression of cell-mediated immunity 
(Avradopoulos 1997; De Waal Malefyt 1991; Taka 1993). High levels of IL-10 
were shown to stimulate plasma B-cell differentiation and thereby contribute to 
the production of auto-antibodies (Melgar 2003). IL-10 has been shown to 
suppress T lymphocyte proliferation and Th1-type inflammatory responses in vivo, 
including lipopolysaccharides-induced endotoxic shock, contact hypersensitivity,
experimental autoimmune encephalomyelitis, collagen-induced arthritis, 
impairment of antigen presentation and blunting of cytotoxic responses (Berg 
1995 J. Clin. Invest.; Berg 1995 J. Exp. Med.; Cua 1999; Apparailly 1998; Ma 
1998; de Waal Malefyt 1991; Taka 1993; Avradopoulos 1997).
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2.5.3.3 Implications of the presence of IL-10
As discussed above, IL-10 exhibits various immunosuppressive effects in vivo. 
Elevated levels of circulating IL-10 were measured in colon cancer patients with 
respect to control and basal IL-10 serum levels were also proven to be a useful 
marker for predicting the recurrence of tumor of colon cancer patients as well as 
the disease-free survival rate. Patients with high IL-10 serum level was 
demonstrated to have an almost sevenfold increased risk of tumor recurrence as 
compared to that of patients with low IL-10 serum level (Galizia 2002 Interferon 
Cytokine Res) (Galizia 2002 Clin. Immunol). Therefore, IL-10 plays a crucial role 
in colon cancer. It was shown by Ebert (2000) that an increase in IL-10 
concentration of less than 1ng/ml was enough to trigger changes in lymphocyte 
proliferation. It was also reported that there is an increase frequency of IL-10 
positive cells seen in colon during ulcerative colitis (Melgar 2003).
2.5.4 Interleukin 8 (IL-8)
IL-8 is an inflammatory cytokine that has been reported to promote tumor cell 
growth in colon cancer cells when activated. IL-8 is a member of the chemokine 
superfamily with structurally and functionally similar inflammatory cytokines. 
IL-8 is produced by a variety of cell types, including basophils, monocytes, 
neutrophils, myoblasts, endothelial cells and epithelial cells in response to 
proinflammatory cytokine or microbial infections (Lindley 1988; McCain 1993; 




Activities of IL-8 are mediated through the binding to its receptors, IL-8RA and 
IL-8RB, which are members of the seven transmembrane G-protein-coupled 
receptor families (Rollins 1997).
2.5.4.2 Functions of IL-8
IL-8 is a potent chemotactic factor for neutrophil (Sparmann 2004). In addition to 
its chemotactic functions, IL-8 has also been reported to promote tumor cell 
proliferation, up-regulate inflammatory responses, act as an autocrine growth 
factor and induce cell migration in colon epithelial cells (Galffy 1999; Wilson 
1999; Brew 1999; Brew 2000; Moser 1993). Studies have demonstrated that IL-8 
is closely associated with the regulation of tumor cell growth and metastasis 
potential in melanoma, carcinoma cells of lung, colon, stomach, pancreas, liver, 
gall bladder, and prostate cancer. (Singh 1994; Kitadai 1998; Inoue 2000; Smith 
1994; Richards 1997; Arenberg 1996). Proinflammatory activity of IL-8 in the 
intestine is mediated via the STAT3 intracellular signal pathway (Keshavarzian 
1999; Nusrat 2001). 
2.5.4.3 Implications of the presence of IL-8
However, there is emerging literature which suggests that constitutive expression 
of IL-8 is linked to metastatic potential in human colon carcinoma cell lines and 
has been suggested to play an essential role in disease states, particularly tumor 
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development and metastasis (Li 2001; Haraguchi 2002). Expression of IL-8 by 
melanoma cells has been shown to regulate growth and metastasis in nude mice, 
as well as being a paracrine factor for melanoma cell chemotaxis (Singh 1994; 
Ramjeesingh 2003). Moreover, there is substantial evidence to prove that IL-8 is a 
critical angiogenic factor in a variety of human cancers (Heidemann 2003). IL-8 is 
not constitutively expressed in tissue due to its strong chemoattractant, 
proinflammatory and angiogenic properties (Mukaida 2003).
2.5.5 Transforming growth factor β1 (TGF-β1)
The TGF-β superfamily includes more than 30 members that are divided into four 
major groups which include (1) the TGF-β themselves, (2) bone morphogenetic 
proteins, (3) activins, and (4) growth/differentiation factors. The mammalian 
TGF-β subfamily consists of three members with similar structures and functions 
i.e. TGF-β1, TGF-β2 and TGF-β3. Transforming growth factor (TGF)-β is a 
protein family which affects multiple cellular functions including survival, 
proliferation, differentiation and adhesion of cells (Bellone 2001).
2.5.5.1 TGF-β1 receptor
TGF-β1 is secreted from mammalian cells as a non-active complex form. A 25kDa 
bioactive dimer which binds through the ubiquitous type I (TGF-β1-RI) and type 
II (TGF-β1-RII) receptors would be released from the non-active complex to a 
wide variety of cell types. They would in turn induce immunosuppression, 
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extracellular matrix deposition, cell cycle arrest and cell differentiation as well as 
apoptosis of normal and neoplastic cells (Massague 1992; Grande 1997). TGF-βs 
are released by platelets and synthesized by various normal cells, including 
activated lymphocytes, macrophages and neutrophils, but also by most 
transformed cells (Van Obberghen Schilling 1988; Yamamoto 1994; Noble 1993; 
Sulitzeanu 1993; Derynck 1985). 
2.5.5.2 Functions of TGF-β1
Transforming growth factor β (TGF-β) belongs to a family of growth factors and 
acts as a primary mechanism to counter Th1 cell-mediated mucosal inflammation 
(Fuss 2002). TGF-β1 is a multipotent cytokine which have an important role in 
regulation of cell growth and development (Roberts 1993; Massague 1996). A 
wide variety of human tumors including many epithelial cancers over-express 
TGF-βs both in vitro and in situ. Over-expression of TGF-β has also been 
observed in tumor tissue of colorectal carcinomas in association with elevated 
TGF-β1 serum levels (Avery 1993; Friedman 1995; Kucharzik 1997). TGF-β1 
was shown to act differently depending on the differentiation stage of the tumor.
TGF-β1 switches from an inhibitor of tumor cell growth in poorly differentiated 
tumors to a stimulator of growth and invasiveness in well-differentiated tumors 
(Hsu 1994; Cui 1996). It was also demonstrated that TGF-β1 can induce a Th2 
cytokine profile in immunocompetent rats with an increased IL-10 and a 
decreased IFN-γ production. (Schiott 1999) 
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2.5.5.3 Implications of the presence of TGF-β1
It was shown in TGF-β knockouts mice that development of various abnormalities 
including symptoms which resemble inflammatory bowel disease (Kulkarni 1993). 
It was reported that elevated expression of TGF-β1, but not TGF-β2 or TGF-β3, 
significantly correlates with the successive progression of colon cancer. Patients 
with elevated levels of TGF-β1 protein in their tumor cells were 18 times more 
likely to experience recurrence of cancer (Friedman 1995). Many tumors were 
also shown to strongly express TGFβ1, which appears to give them a growth 
advantage by suppressing cytolytic immune responses (Chang 1993; Weller 1995; 
Vitolo 1993; Auvinen 1995). Elevated TGF-β1 levels were shown to mediate 
tumor aggressiveness, invasiveness and metastasis in carcinomas (Oft 1998). 
2.6 Chinese Medicine
Western medicine treats diseases and ailments that are visible, structural as well as 
mechanical in nature through the use of synthetically produced drugs and various 
surgical methods. Traditional Chinese Medicine (TCM), on the other hand, does 
not treat structural changes. TCM are based on the treatment of physiological and 
functional imbalances. Western medicine is good for acute cases and for patients 
who need structural repairs, while herbal medicine or acupuncture is good for 
chronic patients who require long term treatment, such as those who require the 
balancing of their physical, mental, and spiritual needs (Joseph Hou 2005).
Literature Review
30
2.6.1 History of Chinese medicine
The beginning of Chinese medicine is traditionally attributed to the legendary 
emperor, Shen Nong, who introduced agriculture and had personally tasted 
hundreds of plants in order to establish their medicinal values (Ho 1997). Records 
of Chinese herbal therapy have been traced back to the third century B.C (Bensky 
1993).
2.6.2 Properties of Chinese herbs
Chinese herbs are used in its natural form or as a whole extract. Based on the 
traditional TCM theory, herbs are classified according to their properties including 
Cold or Warm, sweet or bitter, acrid or tasteless (Joseph Hou 2005). Chinese 
medicine is prescribed as combined herbs formulas, and such prescriptions have 
been proven to be effective through thousands of years of clinical practice. Under 
the TCM theory, the body is viewed as a whole and the laws of herbs combination 
and compatibility in a formula govern the selection of the Chinese herbs. A 
combination formula consisting of two or more herbs is not merely a quantitative 
addition of more herbs, but rather it is the extensive interactions and inter-relations 
among the various herbs with different therapeutic functions in the formula. Each 
herb has a specific role within the formula. Combination herbs formulas work on
differing pharmacological and therapeutic principles from the synthetically 
produced drugs used by modern clinician (Zhang 2000). Patients suffering from 
chronic diseases are then treated slowly using smaller dosages while patients 
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suffering from acute symptoms would require heavy dosages in an attempt to save 
their lives (Joseph Hou 2005).
Chinese practitioner of TCM uses a system of categorizing symptoms and signs to 
differentially assess the presence or absence of certain syndromes for which 
effective herbal formulas and methods are known. (Wiseman 1995) Tumors and 
many cancers share some common tendencies that are commonly manifested in 
specific cases which include stagnation of blood and Qi, accumulation of 
dampness and severe deficiency syndromes associated with a degenerative 
collapse of major body systems (Wicke 2002).
2.6.3 Prevalence of Chinese Medicine usage
World Health Organization has estimated that at least 80 percent of the world 
population relies on traditional medicines for its primary health care needs. 
Studies have also shown that up to 87% of cancer patients under active 
conventional treatment use some form of CAM during their therapy (Downer 
1994).
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3. Materials and methods
3.1 Extraction of herbs
All herbs were kindly provided by Singapore Thong Chai Medical Institution. 
Herbs used include Codonopsis pilosulae (党参), Atractylodes ovata (白术), Poris 
cocos (茯苓), Glycyrrhiza glabra (生甘草), Radix astragali (北芪), Ligustrum 
lucidum (女贞子 ), Paeonia albiflora (白芍 ), Herba sarandrae (肿节风 ), 
Cudraniae radix (穿破石) and Radix actinidiae chinesis (藤梨根).
Herb samples were prepared by adding 1200 ml of distilled water to the combined 
herbs. The herbal mixtures were autoclaved at 115oC for an hour. After 
autoclaving, the herbal extracts were spun at 20,000 x g (Sigma 2K15, USA) for 
15 minutes and the resulting aqueous extracts were then filtered through a coarse 
filter of 1 μm cellulose acetate membrane (Whatman, UK). The filtered herb 
extracts were further filtered through a 0.22 μm cellulose acetate membrane 
(Sartorius, Germany) and were frozen at -80oC for 24 hours. The frozen herbs 
extract was then freeze-dried (Edwards Super Modulyo, UK) to remove all traces 
of water in the extracts.
The dried herb extracts were then weighed and stored at room temperature (RT) in 
a silica gel filled desiccator. 
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The ten individual herbs were prepared by pre-weighing the herbs and distilled 
water was added in their respective weight to volume ratio in the combined herbal
extract. The individual herbs were autoclaved, filtered and freeze-fried as 
described above. The individual herbs were also stored at RT in the desiccator.
3.2 Cell culture
Human intestinal epithelial cells HCT116 (ATCC CCL-247), HT-29 (ATCC 
HTB-38), CaCO-2 (ATCC HTB-37) and ATCC CRL-1790 cells were obtained 
from the American Type Culture Collection (ATCC, Rockville, MD) and cultured 
as monolayers according to instructions provided by the American Type Culture 
Collection. Human colon carcinoma cell line HCT-116 and human colon 
adenocarcinoma cell line HT-29 were routinely cultured in Dulbecco’s Minimum 
Essential Medium (DMEM) containing 10% heat-inactivated fetal bovine serum 
(FBS). CaCO-2, a colorectal adenocarcinoma cell line with normal enterocyte-like
features was cultured in Minimum Essential Medium (MEM) supplemented with 
2 mM L-glutamine, 0.1 mM non-essential amino acids, 1 mM sodium pyruvate 
and 20% heat-inactivated FBS. CRL-1790, normal human colonic cells was 
grown by combining one part of DMEM and one part of Ham’s nutrient mixture 
(F-12), supplemented with 10% heat-inactivated FBS, 0.02 mg/ml insulin, and 50 
nM Hydrocortisone, 0.5 mM sodium pyruvate; 2 mM L-glutamine. DMEM, 
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MEM and DMEM/F-12 were all supplemented with 7.5% w/v sodium bicarbonate, 
10,000 U/ml streptomycin sulfate and 10,000 μg/ml penicillin. All above culture 
media and supplements were obtained from Gibco-BRL, USA.
All cell lines were maintained as monolayer cultures in a humidified 5% CO2
incubator (Hereaus 6220, Germany) at 37oC in 75 cm3 tissue culture flask (Falcon, 
USA). The culture medium was replaced with fresh medium every alternate day. 
When cell reaches 75-85% confluence, the medium was removed and washed 
with phosphate-buffer saline (PBS). The cells were then treated with 
trypsin-EDTA (Gibco-BRL, USA) to dislodge single cells from the flask. Fresh 
medium was added to inactivate the trypsin-EDTA. Cells were distributed into 
new tissue culture flasks with fresh medium. To avoid changes in cell 
characteristics induced by extended cell subcutivation, HCT-116 cells were used 
between Passage 15 and 30, HT-29 cells were used between Passage 13 and 22, 
CaCO-2 cells were used between Passage 25 and 50 and FHC cells were used 
between Passage 7 and 13.
3.2.1 Cell counting and plating of cells
To obtain the desirable cell concentration, cells were trypsinized using 
trypsin-EDTA to obtain single cells. Cells were spun at 115 x g for 5 minutes 
(Sigma 3K15. USA) at 4oC to remove the trypsin and cells were re-suspended in a 
smaller volume of fresh media. One hundred microliter of cell suspension were 
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stained using an equal volume of tryphan blue (Gibco-BRL, USA) and cell count 
was done using the haemocytometer to determine the number of viable cells 
present. One milliliter of 1 X 106 cells was plated into each well of the 6-well 
plate and 3 ml of fresh medium was added for growth. In 96-wells plate, cells 
were plated at a density of 1 X 104 cells per well in a total volume of 100 μl. Cells 
were allowed to adhere to the cell culture plate surface overnight in the incubator.
3.2.2 Cell treatment with herbs
Herbs were pre-weigh and reconstituted in the respective cell culture media to 
their neat concentration. pH of the dissolved herbs were then adjusted to that of 
the cell culture medium to avoid any cell death due to changes in pH of the 
treatment. The dissolved herbs were spun at 4500 x g (Sigma, USA) for 10 
minutes to remove all particulates. The herbal solutions were then filtered 
sterilized using a 0.22 μm syringe filter (Sartorius, Germany). 
Final concentration of the combined herbal treatment used was in the range of 
1.56% to 25% v/v; 12.5% and 25% v/v were used for individual herbal treatment. 
Dilution of the herbal solution was prepared by diluting the neat extracts with cell 
culture medium.
Cell medium were removed from the overnight culture and replace with 3 ml of 
fresh medium per well. 1 ml of the respective diluted herbal solution was added to 
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each well and incubated for 4 and 24 hours in a 5% CO2 incubator.
3.3 Flow cytometry – cell cycle analysis
The proportion of cells in G0-G1, S and G2-M cell cycle phases was determined 
by flow cytometric analysis of DNA content (EPICS Elite ESP cytometer; 
Beckman Coulter, USA). Cells were plated and treated as described in section 
3.2.1 and 3.2.2.
3.3.1 Harvesting and fixation of cells
Cell cycle distribution of the cell after 4 and 24 hours of herbal treatment was 
determined. Cell suspensions of 1 X 106 cells were prepared by removal of any 
floating cells in the cell culture medium and washed with 2 X 1 ml of PBS. All 
washings were collected. The adherent cells were harvested as single cells 
described above with the addition of 200 μl of trypsin-EDTA and then combined 
with the floating dead cells collected. The cells were pelleted by centrifugation at 
720 x g (Sigma, USA) for 10 minutes at 4oC, washed twice with 10 ml of PBS, 
and then resuspended in 500 μl of PBS, fixed and permeabilized by adding 70% 
ice-cold ethanol a drop at a time with shaking between each drop to a final volume 
of 5 ml. Addition of 70% ethanol aided in dye access to DNA in intact cells and 
allowing DNA content analysis of stained cells by flow cytometry. Cell
suspension was then stored at -20oC until further analysis. 
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3.3.2 Flow analysis
Ethanol-fixed cell suspension was spun at 4500 x g (Sigma, USA) for 10 minutes 
at 4oC to pellet the cells. Ethanol was discarded and cell pellets were allowed to 
air-dry. Air-dried cell pellets were then stained with 500 μl Fluorescence Activated 
Cell Sorting (FACS) DNA staining buffer containing 1 mg/ml propidium iodide 
(PI) (Sigma, USA) and 880 Kunitz units/ml RNase A (Sigma, USA) and incubated 
in the dark for 30 minutes at RT. Cell samples were filtered through a 41um nylon 
filter to remove any cell clumps and then subjected to flow cytometry analysis.
Cell cycle distribution in the human colonic cells was determined after 4 and 24 
hours of various herbal treatments. The distribution of PI-stained cells suspension 
in G0 (sub G1), G1, S, and G2/M cell cycle phases were determined by flow 
cytometric analysis of DNA content by Coulter EPICS Elite ESP flow cytometer 
(Beckman, USA) with an argon laser emitting at 488 nm. Data were acquired and 
statistical analysis of the DNA histogram was performed using Windows Multiple 
Document Interface for Flow Cytometry Application (WinMDI software Version 
2.8) to evaluate cell cycle compartments. Statistical analysis was performed using 
the SPSS statistical analysis software. Comparisons between the mean of the 
various treatment groups were analyzed using one-way ANOVA. The difference 
was considered significant when P<0.05. 
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3.4 Enzyme-Linked Immunosorbent Assay (ELISA)
The BD OptEIA™ test is a solid phase sandwich ELISA which utilizes 
monoclonal antibody specific for human cytokines coated on a 96-well plate. 
Standards and samples were added to the wells and the specific cytokines present 
would bind to the immobilized antibody. The wells were washed and biotinylated 
anti-human antibody was added, producing an antibody- antigen- antibody 
“sandwich”. After the second wash, Streptavidin-horseradish peroxidase was 
added. The wells were again washed and Tetramethylbenzidine (TMB) substrate 
solution was added, which produced a blue color in direct proportion to the 
amount of cytokine present in the initial sample. The stop solution changes the 
color from blue to yellow, and the wells were read at 450 nm.
BD OptEIATM Set was used to test for Human IL-4, IL-8 and IL-10 and TGF-β1 
(BD Bioscience Pharmingen, USA).
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3.4.1 Cell plating and treatment 
All 4 cell lines were used. In the 6-well plates, 1 X 106 cells per well were 
cultured in their respective medium and allowed to adhere overnight. Cells were 
treated with both combined herbal extract as well as individual herbs that had 
previously shown to increase cell death by cell cycle analysis. Triplicates were 
performed for all conditions and cells were incubated at 5% CO2, 37
oC for 4 and 
24 hours. 
3.4.2 Sample collection
After incubation, cell supernatants were collected in 1.5 ml eppendorf tubes and 
spun at 12,000 x g for 10 minutes at 4oC (Beckman Coulter Microfuge, USA) to 
remove any particulate materials. Samples were aliquoted into new eppendorf 
tubes of 400 μl each, to avoid repeated freeze-thawing and, stored at -20oC. 
3.4.3 Standard curves
Standards were reconstituted and aliquots of 50 μl each were stored at -70oC. 
For TGF-β1, a 4000 pg/ml standard was prepared from the stock solution using 
assay diluent (PBS with 10% FBS, pH 7.0). Serial dilutions were performed using 
assay diluent to obtain concentrations of 2000 pg/ml, 1000 pg/ml, 500 pg/ml, 250 
pg/ml, 125 pg/ml and 62.5 pg/ml. Assay diluent was used as the blank (0 pg/ml).
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For IL-4 and IL-10, a 500 pg/ml standard was prepared from the stock solution 
using assay diluent. Serial dilutions were performed using assay diluent to 
obtained concentrations of 250 pg/ml, 125 pg/ml, 62.5 pg/ml, 31.3 pg/ml, 15.6 
pg/ml and 7.8 pg/ml. Assay diluent was used as the blank (0 pg/ml).
For IL-8, a 200 pg/ml standard was prepared from the stock solution using assay 
diluent. Serial dilutions were performed using assay diluent to obtained 
concentrations of 100 pg/ml, 50 pg/ml, 25 pg/ml, 12.5 pg/ml, 6.3 pg/ml and 3.1 
pg/ml. Assay diluent was used as the blank (0 pg/ml)
3.4.4 Measurement of cytokine production
Ninety six-microwells plates (BD FalconTM ELISA plates, USA) were used. Plates 
were pre-coated with 100 μl per well of diluted monoclonal capture antibody 
against IL-4, IL-8, IL-10 and TGF-β1, sealed and incubated overnight at 4oC. The 
monoclonal capture antibodies were diluted in coating buffer in the dilution factor 
as specified in the instruction of the kit. Wells were washed three times with 300 
μl/well of wash buffer. Plates were inverted and blotted on absorbent paper to 
remove any residual buffer. Blocking was done by adding 200 μl of assay diluent 
and incubated at RT for an hour. Plates were washed three times with 300 μl wash 
buffer. Triplicates of 100 μl of each standards, controls and samples were pipetted 
into the appropriate wells. Plates were sealed and incubated for two hours at RT. 
Plates were washed five times with 300 μl washing buffer, and 100 μl of their 
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respective working detector was added to each well and incubated at RT for an 
hour. Working detector was prepared by addition of the respective biotinylated 
anti- IL-4, IL-8, IL-10 and TGF-β1 antibodies with horse radish peroxidase 
(HRP)-labeled strepavidin enzyme reagent in their specified dilution to the assay 
diluent 15 minutes prior to use. Plates were then washed seven times with 300 μl 
wash buffer. Substrate solution made up of equal proportion of 
Tetramethylbenzidine (TMB) and Hydrogen Peroxide (BD PharmingenTM TMB 
Substrate Reagent Set, USA) were premixed and 100 μl was added to each well 
and incubated at RT in the dark for thirty minutes. The reaction was stopped by 
adding 1M phosphoric acid. Absorbance values were read at 450 nm corrected 
with absorbance at 570 nm using an ELISA TouchScreen plate reader (Tecan, 
Austria) running in Magellan2 software. Cytokine concentration was calculated by 
linear regression.
3.4.5 Analysis
Cytokine concentration of samples and controls were determined. Comparisons of 
cytokine up- or down-regulation in herb-treated cells were made against the 
controls.
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3.5 Apoptotic DNA laddering kit
Apoptotic DNA ladder kit from Roche Applied Science (USA) was used. The 
apoptotic DNA ladder kit is designed for the purification of nucleic acids from 
cells to detect DNA ladder, which is the hallmark of apoptotic cells. 
3.5.1 Sample collection 
Cells were plated and treated as described in section 3.2.1 and 3.2.2. All four cell 
lines were used and herbal treatment which previously showed increased cell 
death by cell cycle analysis at their respective concentrations was used. Apoptosis 
was induced in all four cell lines with the addition of 35 nM Staurosporine (Sigma, 
USA) and 5 mM sodium butyrate (Merck, USA). Six wells of 1 X 106 cells per 
well were plated in 6-wells plate for each condition. One well of adhered cells 
with all six wells of floating cells in the supernatant was collected and cells were 
pelleted and washed twice with 10 ml PBS. Cell pellets were then re-suspended in 
200 μl of PBS and an equal volume of lysis buffer was added and mixed. The 
lysed suspension was incubated for 10 minutes at RT. After incubation, 100 μl of 
isopropanol was added and all 500 μl of lysed samples were transferred to a spin 
column and centrifuged at 5700 x g for 1 minute. The flow through was discarded 
and the spin columns were washed twice with washing buffer. DNA was finally 
eluted using elution buffer that was pre-warmed to 70oC. DNA samples were 
stored at -20oC for later analysis.
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3.5.2 Quantification and preparation of DNA
DNA concentrations of the DNA samples were quantified using Nanodrop 
(Nanodrop ND-1000, USA). Two μg of purified DNA samples were mixed with 
10X loading dye.
3.5.3 1% Agarose- DNA gel preparation
One g of agarose (Cambrex, USA) was weighed into an Erlenmeyer-flask and 100 
ml of TBE-buffer was added. Agarose- TBE solution was microwaved until the 
agarose was completely dissolved. Two μl of ethidium bromide solution (ICN 
Biomedicals, USA) was added to the warmed agarose solution. The solution was 
poured into the pre-prepared electrophoresis chamber with the gel comb. After the 
gel had hardened, the tape and gel comb was removed.
3.5.4 Running of gel
DNA samples and a 100 bp DNA ladder were loaded and electrophoresis was 
carried out at 75 volts for one and a half hour in 1X TBE buffer. Power supply 
was turn off when the bromophenol blue dye front had migrated to the end of the 
platform. The DNA samples were visualized in ultraviolet light at 254 nm using 
an Imaging system (Bio-Rad, USA) running on Quantity One software.
                                             Materials and Methods
44
3.5.5 Analysis
DNA samples which showed similar laddering pattern as those of the apoptosis 
induced by staurosporine and sodium butyrate were deemed to have undergone 
apoptosis.
3.6 Cytotoxicity assay
In necrotic cells, stable cytosolic enzyme, lactate dehydrogenase (LDH) is 
released from the cells. Cytotoxicity assay is a measurement of the amount of 
necrotic cell death by monitoring the activity of LDH through colorimeteric assay. 
Released LDH in culture supernatants was measured with a 30-minute coupled 
enzymatic assay, which results in the conversion of a tetrazolium salt into a red 
formazan product. The amount of color formed was proportional to the number of 
lysed cells. Visible wavelength absorbance data were collected at 490 nm using a 
standard 96-well plate reader. 
3.6.1 Cell plating and treatment
Ninety six-well tissue-cultured round-bottom plate (Nunc, Denmark) was used 
and 1 X 104 cells were plated per well. Cells were treated with the herbs at the 
same concentration that was previously shown to have an increased cell death 
when analyzed with cell cycle analysis. Induction of necrosis was done by 
incubating cells with 0.5 M sodium chloride and 0.5 M sodium butyrate. Cells 
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were incubated at 37oC, 5% CO2 for 4 and 24 hours and then spun at 250 x g 
(Sigma, USA) for 4 minutes at 4oC. 
Cytotoxicity assay was carried out with the use of CytoTox96 Non-Radioactive 
Cytotoxicity Assay (Promega, USA). Fifty μl of supernatant from all treated wells 
were transferred using a multichannel pipettor to a fresh 96-well flat-bottom plate 
(Nunc, Denmark). Substrate mix was reconstituted by adding 12 ml of assay 
buffer. Fifty microliter of the reconstituted substrate mixture was added to each 
well containing sample and incubated at room temperature for half hour, away 
from light. After incubation, 50 μl of stop solution was added to each well. 
Absorbance was measured at 490 nm using an ELISA TouchScreen plate reader 
(Tecan, Austria) running in Magellan2 software.
3.6.2 Analysis
The data was compared to that of control as well as wells with necrotic cells 
induced with sodium chloride and sodium butyrate. Herbal treatment with 
increased LDH concentration similar to that of the chemically-induced necrosis 
indicated that they caused increase cell death by necrosis.
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3.7 Statistical Analysis
Data were expressed as mean ± SD and statistical analyzed by One-way ANOVA 
and Post Hoc tests to compare between the various treatments. Level of 





4.1 Flow cytometry DNA cell cycle analysis of combined herbal-treated human 
colonic cells
Percentages of cell death as well as cell cycle arrest in human colonic cells after 
herbal treatment were determined using flow cytometry with the aid of propidium 
iodide, a DNA-intercalating stain. Time (4 and 24 hours) and dosage (1.56-25% v/v)
dependent herbal treatments were performed on all four cell line, namely HCT-116, 
HT-29, CaCO-2 and CRL-1790. 
All four cell lines when treated with combined herbal extract showed increased cell
death as indicated by the accumulation of cells in sub-G1 with a corresponding 
reduction in the percentage of cells in G1 in a time and dosage-dependent manner
(Fig 4.1-4.8). No cell cycle arrest was observed in HCT-116, CaCO-2 and 
CRL-1790 when treated with combined herbs as shown in Fig 4.1-4.4 and Fig 
4.7-4.8. The highest degree of cell death measured was approximately 15%, 25% 
and 37% sub-G1 increment in HCT-116, CaCO-2 and CRL-1790 respectively (Fig 
4.1-4.4 and Fig 4.7-4.8) (p<0.05). In HT-29 cells treated with combined herbs, the 
cell cycle was arrested at G2/M phase prior to cell death at 25% v/v combined herbs
(Fig 4.6). Drastic accumulation of cells in the G2/M phase in HT-29 cells was 
observed after exposure to 12.5% v/v combined herbs for 24 hours. Cells in the G1
phase concomitantly decreased. 
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Fig. 4.1 Flow cytometry cell cycle analysis of HCT-116 cells treated with combined 
herbs at 4 hours post treatment. Each value is represented as mean ± SD (n = 6)




















Fig 4.2 Flow cytometry cell cycle analysis of HCT-116 cells treated with combined 
herbs at 24 hours post treatment. Each value is represented as mean ± SD (n = 6)
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Fig 4.3 Flow cytometry cell cycle analysis of CaCO-2 cells treated with combined 
herbs at 4 hours post treatment. Each value is represented as mean ± SD (n = 6)



















Fig 4.4 Flow cytometry cell cycle analysis of CaCO-2 cells treated with combined 
herbs at 24 hours post treatment. Each value is represented as mean ± SD (n = 6)
Results
50



















Fig 4.5 Flow cytometry cell cycle analysis of HT-29 cells treated with combined 
herbs at 4 hours post treatment. Each value is represented as mean ± SD (n = 6)





















Fig 4.6 Flow cytometry cell cycle analysis of HT-29 cells treated with combined 
herbs at 24 hours post treatment. Each value is represented as mean ± SD (n = 6)
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Fig 4.7 Flow cytometry cell cycle analysis of CRL-1790 cells treated with 
combined herbs at 4 hours post treatment. Each value is represented as mean ± SD 
(n = 6)





















Fig 4.8 Flow cytometry cell cycle analysis of CRL-1790 cells treated with 




4.2 Flow cytometry DNA cell cycle analysis of individual herbal-treated human 
colonic cells
As shown in Fig 4.1 to Fig 4.8, all four human colonic cells underwent increase cell 
death when treated with combined herbs. Most significant amount of cell death was 
observed at concentration of 12.5% v/v and 25% v/v combined herbs. These two 
concentrations were then used to test for individual herbs on all four colonic cells. 
Cell cycle analysis using flow cytometry was done to determine the effect of the 
individual herbs.
In HCT-116 cells, of the ten individual herbs tested, only HS and RAC were shown 
to cause significant increase in cell death with 12% and 15% increment in sub-G1
respectively as shown in Fig 4.16 and 4.18 (p<0.05). GG on the other hand lead to a 
lesser degree of cell death with approximately 1% significant increase in cell death 
at 25% v/v concentration at 24 hours with 95% confidence interval (Fig 4.13)
(p<0.05). Cell cycle arrest at G1 was observed in LL-treated HCT-116 cells (Fig 
4.14(B)). HCT-116 when treated with a combination of RAC and HS as shown in 
Fig 4.19, showed a 50% increase in cell death at 24 hours compared to 15% 
increase in cell death when treated with total combined herbs (Fig 4.2), and HS 
(12%) (Fig 4.16) and RAC (15%) (Fig 4.18) individually (p<0.05).
Slight increase in cell death was observed in CaCO-2 when treated with all ten 
individual herbal treatments, but only HS and CR showed significant in cell death 
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as compared to control cells. A 1.5% and 3% increase in cell death was observed in 
CaCO-2 cells treated with HS and CR respectively as shown in Fig 4.27 and Fig 
4.28 (p<0.05). G2/M arrest was observed in CP and CR-treated CaCO-2 at 24 hours 
post treatment as shown in Fig 4.20 (B) and Fig 4.28 (B). Combinatorial effects 
exerted by individual herbs on CaCO-2 correspond to cell death observed when 
treated with combined herbs. 
As shown in Fig 4.37 and Fig 4.38, HS and CR caused increase cell death in HT-29 
cells with an increase of approximately 1.5% and 4% sub-G1 respectively (p<0.05). 
Significant G2/M arrest was observed in RA, GG and HS-treated HT-29 cells with a 
corresponding decrease in percentage of cells in G1.
In CRL-1790, three out of the ten herbs induced significant increase in cell death. 
The three herbs are PA, HS and RAC with 1.5%, 1% and 2% increase in cell death 
respectively (p<0.05). The increase in cell death observed in HT-29 and CRL-1790 
when treated with individual herbs was much lower as compared to that of the 
combined herbs. This could possibly indicate that combinatorial effect between the 

































Fig 4.9 (A) and (B) Flow cytometry cell cycle analysis of HCT-116 cells treated 
with CP at 4 and 24 hours post treatment. Each value is represented as mean ± SD
(n = 3)
































Fig 4.10 (A) and (B) Flow cytometry cell cycle analysis of HCT-116 cells treated 
with AO at 4 and 24 hours post treatment. Each value is represented as mean ± SD 
(n = 3)





























Fig 4.11 (A) and (B) Flow cytometry cell cycle analysis of HCT-116 cells treated 





































Fig 4.12 (A) and (B) Flow cytometry cell cycle analysis of HCT-116 cells treated 
with RA at 4 and 24 hours post treatment. Each value is represented as mean ± SD 
(n = 3)































Fig 4.13 (A) and (B) Flow cytometry cell cycle analysis of HCT-116 cells treated 
with GG at 4 and 24 hours post treatment. Each value is represented as mean ± SD 
(n = 3)
































Fig 4.14 (A) and (B) Flow cytometry cell cycle analysis of HCT-116 cells treated 





































Fig 4.15 (A) and (B) Flow cytometry cell cycle analysis of HCT-116 cells treated 
with PA at 4 and 24 hours post treatment. Each value is represented as mean ± SD 
(n = 3)
































Fig 4.16 (A) and (B) Flow cytometry cell cycle analysis of HCT-116 cells treated 
with HS at 4 and 24 hours post treatment. Each value is represented as mean ± SD 
(n = 3)































Fig 4.17 (A) and (B) Flow cytometry cell cycle analysis of HCT-116 cells treated 






































Fig 4.18 (A) and (B) Flow cytometry cell cycle analysis of HCT-116 cells treated 
with RAC at 4 and 24 hours post treatment. Each value is represented as mean ± SD 
(n = 3)


































Fig 4.19 (A) and (B) Flow cytometry cell cycle analysis of HCT-116 cells treated 
with combination of RAC and HS at 4 and 24 hours post treatment. Each value is 
represented as mean ± SD (n = 3)
CaCO-2































Fig 4.20 (A) and (B) Flow cytometry cell cycle analysis of CaCO-2 cells treated 






































Fig 4.21 (A) and (B) Flow cytometry cell cycle analysis of CaCO-2 cells treated 
with AO at 4 and 24 hours post treatment. Each value is represented as mean ± SD 
(n = 3)































Fig 4.22 (A) and (B) Flow cytometry cell cycle analysis of CaCO-2 cells treated 
with PC at 4 and 24 hours post treatment. Each value is represented as mean ± SD 
(n = 3)
































Fig 4.23 (A) and (B) Flow cytometry cell cycle analysis of CaCO-2 cells treated 





































Fig 4.24 (A) and (B) Flow cytometry cell cycle analysis of CaCO-2 cells treated 
with GG at 4 and 24 hours post treatment. Each value is represented as mean ± SD 
(n = 3)






























Fig 4.25 (A) and (B) Flow cytometry cell cycle analysis of CaCO-2 cells treated 
with LL at 4 and 24 hours post treatment. Each value is represented as mean ± SD 
(n = 3)































Fig 4.26 (A) and (B) Flow cytometry cell cycle analysis of CaCO-2 cells treated 






































Fig 4.27 (A) and (B) Flow cytometry cell cycle analysis of CaCO-2 cells treated 
with HS at 4 and 24 hours post treatment. Each value is represented as mean ± SD 
(n = 3)






























Fig 4.28 (A) and (B) Flow cytometry cell cycle analysis of CaCO-2 cells treated 
with CR at 4 and 24 hours post treatment. Each value is represented as mean ± SD 
(n = 3)






























Fig 4.29 (A) and (B) Flow cytometry cell cycle analysis of CaCO-2 cells treated 








































Fig 4.30 (A) and (B) Flow cytometry cell cycle analysis of HT-29 cells treated with 
CP at 4 and 24 hours post treatment. Each value is represented as mean ± SD (n = 3)
































Fig 4.31 (A) and (B) Flow cytometry cell cycle analysis of HT-29 cells treated with 
AO at 4 and 24 hours post treatment. Each value is represented as mean ± SD (n = 
3)
































Fig 4.32 (A) and (B) Flow cytometry cell cycle analysis of HT-29 cells treated with 








































Fig 4.33 (A) and (B) Flow cytometry cell cycle analysis of HT-29 cells treated with 
RA at 4 and 24 hours post treatment. Each value is represented as mean ± SD (n = 
3)

































Fig 4.34 (A) and (B) Flow cytometry cell cycle analysis of HT-29 cells treated with 
GG at 4 and 24 hours post treatment. Each value is represented as mean ± SD (n = 
3)


































Fig 4.35 (A) and (B) Flow cytometry cell cycle analysis of HT-29 cells treated with 







































Fig 4.36 (A) and (B) Flow cytometry cell cycle analysis of HT-29 cells treated with 
PA at 4 and 24 hours post treatment. Each value is represented as mean ± SD (n = 3)



































Fig 4.37 (A) and (B) Flow cytometry cell cycle analysis of HT-29 cells treated with 
HS at 4 and 24 hours post treatment. Each value is represented as mean ± SD (n = 
3)


































Fig 4.38 (A) and (B) Flow cytometry cell cycle analysis of HT-29 cells treated with 











































Fig 4.39 (A) and (B) Flow cytometry cell cycle analysis of HT-29 cells treated with 
RAC at 4 and 24 hours post treatment. Each value is represented as mean ± SD (n = 
3)
CRL-1790



































Fig 4.40 (A) and (B) Flow cytometry cell cycle analysis of CRL-1790 cells treated 
with CP at 4 and 24 hours post treatment. Each value is represented as mean ± SD 
(n = 3)



































Fig 4.41 (A) and (B) Flow cytometry cell cycle analysis of CRL-1790 cells treated 










































Fig 4.42 (A) and (B) Flow cytometry cell cycle analysis of CRL-1790 cells treated 
with PC at 4 and 24 hours post treatment. Each value is represented as mean ± SD 
(n = 3)



































Fig 4.43 (A) and (B) Flow cytometry cell cycle analysis of CRL-1790 cells treated 
with RA at 4 and 24 hours post treatment. Each value is represented as mean ± SD 
(n = 3)



































Fig 4.44 (A) and (B) Flow cytometry cell cycle analysis of CRL-1790 cells treated 










































Fig 4.45 (A) and (B) Flow cytometry cell cycle analysis of CRL-1790 cells treated 
with LL at 4 and 24 hours post treatment. Each value is represented as mean ± SD 
(n = 3)



































Fig 4.46 (A) and (B) Flow cytometry cell cycle analysis of CRL-1790 cells treated 
with PA at 4 and 24 hours post treatment. Each value is represented as mean ± SD 
(n = 3)





































Fig 4.47 (A) and (B) Flow cytometry cell cycle analysis of CRL-1790 cells treated 










































Fig 4.48 (A) and (B) Flow cytometry cell cycle analysis of CRL-1790 cells treated 
with CR at 4 and 24 hours post treatment. Each value is represented as mean ± SD 
(n = 3)



































Fig 4.49 (A) and (B) Flow cytometry cell cycle analysis of CRL-1790 cells treated 






4.3 Immunomodulatory effects of herbs on human colonic cells
4.3.1 Effect of combined herbs on human colonic cells
Level of IL4, an anti-inflammatory cytokine, was determined in all four colonic cell 
lines. As shown in Fig 4.50, concentration of secreted IL-4 from HCT-116 cells was 
shown to peak with approximately 13 pg/ml IL-4 between 1.56% to 3.125% v/v 
combined herbal treatment, after which IL-4 concentration dropped with increasing 
combined herbal concentration. IL-4 concentration of CaCO-2 and HT-29 cells 
were shown to peak with approximately 2-3 pg/ml IL-4 at 25% v/v combined herbs 
at 4 hours post-treatment after which little or no IL-4 was measured (Fig 4.54 and 
Fig 4.58). This could indicate the short lifespan of IL-4 or short production period 
of the cytokine by CaCO-2 and HT-29. Increasing concentration of IL-4 was 
measured in combined herbal-treated CRL-1790 up to a maximum concentration of 
16 pg/ml at 4 hours post treatment. However, the cytokine level drop to 6 pg/ml 
after 24 hours incubation (Fig 4.62).
In all four cell lines, high level of inflammatory cytokine IL-8 was measured in the 
control cells. Level of IL-8 dropped drastically in all cell lines with increasing 
combined herbal concentrations (Fig 4.51, Fig 4.55, Fig 4.59, Fig 4.63).
IL-10 showed a similar trend to that of IL-4 level in HCT-116 with cytokine 
concentration peaked between 1.56% to 3.125% v/v combined herbs followed by a 
decreasing trend (Fig 4.52). In CaCO-2 cells, an increasing concentration of IL-10 
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was measured which peak at 25% v/v combined herbs at 4 hours. Similar trends 
were also observed at 24 hours but at a lower concentration (Fig 4.56). However, 
there was a decreasing trend of IL-10 production in HT-29 with increasing 
concentration of herbal concentration and with increasing incubation period (Fig 
4.60). In CRL-1790, high concentration of combined herbs require shorter time 
period for IL-10 induction after which the concentration drop from approximately 
2.5 pg/ml to 0.5 pg/ml with increasing incubation time (Fig 4.64). 
Combined herbs were shown to cause a total drop in TGF-β1 level in all four cell 
lines as compared to that of the control cells (Fig 4.53, Fig 4.57, Fig 4.61, Fig 4.65).
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Fig 4.50 Concentration of IL-4 produced by HCT-116 when treated with combined 
herbs. Each value is represented as mean ± SD (n = 3)






























Fig 4.51 Concentration of IL-8 produced by HCT-116 when treated with combined 
herbs. Each value is represented as mean ± SD (n = 3)
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Fig 4.52 Concentration of IL-10 produced by HCT-116 when treated with combined 
herbs. Each value is represented as mean ± SD (n = 3)





























Fig 4.53 Concentration of TGF-β1 produced by HCT-116 when treated with 
combined herbs. Each value is represented as mean ± SD (n = 3)
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Fig 4.54 Concentration of IL-4 produced by CaCO-2 when treated with combined 
herbs. Each value is represented as mean ± SD (n = 3)






























Fig 4.55 Concentration of IL-8 produced by CaCO-2 when treated with combined 
herbs. Each value is represented as mean ± SD (n = 3)
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Fig 4.56 Concentration of IL-10 produced by CaCO-2 when treated with combined 
herbs. Each value is represented as mean ± SD (n = 3)


























Fig 4.57 Concentration of TGF-β1 produced by CaCO-2 when treated with 
combined herbs. Each value is represented as mean ± SD (n = 3)
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Fig 4.58 Concentration of IL-4 produced by HT-29 when treated with combined 
herbs. Each value is represented as mean ± SD (n = 3)




























Fig 4.59 Concentration of IL-8 produced by HT-29 when treated with combined 
herbs. Each value is represented as mean ± SD (n = 3)
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Fig 4.60 Concentration of IL-10 produced by HT-29 when treated with combined 
herbs. Each value is represented as mean ± SD (n = 3)































Fig 4.61 Concentration of TGF-β1 produced by HT-29 when treated with combined 
herbs. Each value is represented as mean ± SD (n = 3)
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Fig 4.62 Concentration of IL-4 produced by CRL-1790 when treated with combined 
herbs. Each value is represented as mean ± SD (n = 3)






























Fig 4.63 Concentration of IL-8 produced by CRL-1790 when treated with combined 
herbs. Each value is represented as mean ± SD (n = 3)
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Fig 4.64 Concentration of IL-10 produced by CRL-1790 when treated with 
combined herbs. Each value is represented as mean ± SD (n = 3)






























Fig 4.65 Concentration of TGF-β1 produced by CRL-1790 when treated with 
combined herbs. Each value is represented as mean ± SD (n = 3)
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4.3.2 Effect of individual herbs on human colonic cells
RAC and HS were shown to cause an increase in IL-4 level in HCT-116 with 
increasing concentration and with increasing time period of exposure. However, no 
IL-4 was measured when HCT-116 was treated with GG. Similar trends were 
observed when cell supernatants were assayed for IL-10. A direct reverse trend was 
observed in IL-8 concentration when treated with RAC, HS and GG. Concentration 
of TGF-β1 drop drastically when HCT-116 was treated with RAC and HS which 
indicates that RAC and HS inhibited the production of TGF-β1. GG on the other 
hand only caused a slight drop in level of TGF-β1.
Negligible amount of IL-4 of less than 1 pg/ml was measured in 4 hours post 
HS-treated CaCO-2 after which it dropped to below measurable level at 24 hours. 
Low level of IL-4 was measured in CaCO-2 at 24 hours after treatment with CR. 
IL-10 production was shown to be up-regulated in CaCO-2 cells when treated with 
HS which peaks at 4 hours. No IL-10 was measured in CR-treated CaCO-2. 
Down-regulation of IL-8 production was observed in HS-treated CaCO-2 while 
up-regulation of IL-8 was observed in CR-treated CaCO-2. Slight up-regulation of 
TGF-β1 was observed in 24 hours in 12.5% v/v CR-treated CaCO-2.
Increased concentration of IL-4 and IL-8 was measured when HT-29 cells were 
treated with CR. However, presence of CR inhibited the production of IL-10 as well 




No significant changes in IL-4 and IL-8 concentration were measured in RAC, HS 
and PA-treated CRL-1790. IL-10 was shown to be down-regulated in CRL-1790 
when treated with RAC, HS as well as PA. RAC and HS inhibited the production of 
TGF-β1 in CRL-1790 cells while PA did not have any effect on CRL-1790 
production of TGF-β1.



























Fig 4.66 Concentration of IL-4 produced by HCT-116 cells when treated with RAC, 
HS and GG. Each value is represented as mean ± SD (n = 3)
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Fig 4.67 Concentration of IL-8 produced by HCT-116 cells when treated with RAC, 
HS and GG. Each value is represented as mean ± SD (n = 3)


























Fig 4.68 Concentration of IL-10 produced by HCT-116 cells when treated with 
RAC, HS and GG. Each value is represented as mean ± SD (n = 3)
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Fig 4.69 Concentration of TGF-β1 produced by HCT-116 cells when treated with 
RAC, HS and GG. Each value is represented as mean ± SD (n = 3)






















Fig 4.70 Concentration of IL-4 produced by CaCO-2 cells when treated with HS 
and CR. Each value is represented as mean ± SD (n = 3)
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Fig 4.71 Concentration of IL-8 produced by CaCO-2 cells when treated with HS 
and CR. Each value is represented as mean ± SD (n = 3)























Fig 4.72 Concentration of IL-10 produced by CaCO-2 cells when treated with HS 
and CR. Each value is represented as mean ± SD (n = 3)
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Fig 4.73 Concentration of TGF-β1 produced by CaCO-2 cells when treated with HS 
and CR. Each value is represented as mean ± SD (n = 3)

























Fig 4.74 Concentration of IL-4 produced by HT-29 cells when treated with HS and 
CR. Each value is represented as mean ± SD (n = 3)
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Fig 4.75 Concentration of IL-8 produced by HT-29 cells when treated with HS and 
CR. Each value is represented as mean ± SD (n = 3)
























Fig 4.76 Concentration of IL-10 produced by HT-29 cells when treated with HS and 
CR. Each value is represented as mean ± SD (n = 3)
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Fig 4.77 Concentration of TGF-β1 produced by HT-29 cells when treated with HS 
and CR. Each value is represented as mean ± SD (n = 3)





























Fig 4.78 Concentration of IL-4 produced by CRL-1790 cells when treated with 
RAC, HS and PA. Each value is represented as mean ± SD (n = 3)
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Fig 4.79 Concentration of IL-8 produced by CRL-1790 cells when treated with 
RAC, HS and PA. Each value is represented as mean ± SD (n = 3)


























Fig 4.80 Concentration of IL-10 produced by CRL-1790 cells when treated with 
RAC, HS and PA. Each value is represented as mean ± SD (n = 3)
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Fig 4.81 Concentration of TGF-β1 produced by CRL-1790 cells when treated with 
RAC, HS and PA. Each value is represented as mean ± SD (n = 3)
Results
88
4.4 Mechanism of cell death
4.4.1 DNA laddering assay (Apoptosis)
Staurosporine and sodium butyrate were used as positive control. As shown in Fig 
4.82, slight fragmentation indicative of apoptosis observed in 4 hours treatment of 
HCT-116 with 25% v/v combined herbs, 25% v/v RAC, 12.5% v/v HS and 25% v/v 
HS and 24 hours treatment with 12.5% v/v RAC, 25% v/v RAC and 25% v/v GG. 
Greater degree of DNA fragmentation was seen when HCT-116 was treated with 
12.5% v/v combined herbs, 12.5% v/v HS and 25% v/v HS at 24 hours. DNA 
smearing was seen in 24 hours treatment of HCT-116 with 25% v/v combined 
herbs.
Fig 4.82 HCT-116 cells treated with combined as well as individual herbs for 4 and
24 hours. Lane (1) 4h Control (2) 4h 1 μM Staurosporine (3) 4h 5 mM NaB (4) 4h 
25% v/v combined herbs (5) 4h 25% v/v RAC (6) 4h 12.5% v/v HS (7) 4h 25% v/v 
HS (8) 24h Ctrl (9) 24h 1 μM Staurosporine (10) 24h 5 mM NaB (11) 24h 12.5% 
v/v combined herbs (12) 24h 25% v/v combined herbs (13) 24h 12.5% v/v RAC (14) 
24h 25% v/v RAC (15) 24h 12.5% v/v HS (16) 24h 25% v/v HS (17) 24h 25% v/v 
GG. The arrow indicates DNA fragmentation observed when the cells undergo 
apoptosis.
1  2   3   4   5   6   7   8   9 10    11 12 13 14 15 16 17
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Apoptosis was observed in CaCO-2 when treated with combined herbs, HS and CR 
in both 4 and 24 hours treatment (Fig 4.84).
Fig 4.83 CaCO-2 cells treated with combined as well as individual herbs for 4 and
24 hours. Lane (1) 4h Control (2) 4h 1 μM Staurosporine (3) 4h 5 mM NaB (4) 4h 
12.5% v/v combined herbs (5) 4h 25% v/v combined herbs (6) 4h 25% v/v HS (7) 
4h 25% v/v CR (8) 24h Ctrl (9) 24h 1 μM Staurosporine (10) 24h 5 mM NaB (11) 
24h 3.125% v/v combined herbs (12) 24h 6.25% v/v combined herbs (13) 24h 
12.5% v/v combined herbs (14) 24h 25% v/v combined herbs (15) 24h 25% v/v HS 
(16) 24h 25% v/v CR. The arrow indicates DNA fragmentation observed when the 
cells undergo apoptosis.
1   2 3   4   5 6 7      8 9    10 11 12  13 14 15 16
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DNA fragmentation was observed in HT-29 with 4 hours CR treatment; and in both 
4 and 24 hours treatment with HS (Fig 4.83). DNA smearing was observed in 24 
hours treatment of HT-29 cells with 25% v/v combined herbs and 25% v/v HS.
Fig 4.84 HT-29 cells treated with combined as well as individual herbs for 4 and 24 
hours. Lane (1) 4h Control (2) 4h 1 μM Staurosporine (3) 4h 5 mM NaB (4) 4h 
12.5% v/v HS (5) 4h 25% v/v HS (6) 24h Ctrl (7) 24h 1 μM Staurosporine (8) 24h 5
mM NaB (9) 24h 25% v/v combined herbs (10) 24h 12.5% v/v HS (11) 24h 25% 
v/v HS (12) 24h 25% v/v CR. The arrow indicates DNA fragmentation observed 
when the cells undergo apoptosis.
1 2 3 4 5     6   7 8 9 10 11 12
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DNA smearing was observed in both 4 and 24 hours treatment of CRL-1790 cells 
with 25% v/v combined herbs (Fig 4.85). No visible DNA fragmentation seen in 
RAC, HS and PA treatment of CRL-1790 cells.
Fig 4.85 CRL-1790 cells treated with combined as well as individual herbs for 4 
and 24 hours. Lane (1) 4h Control (2) 4h 1 μM Staurosporine (3) 4h 5 mM NaB (4) 
4h 25% v/v combined herbs (5) 4h 12.5% v/v RAC (6) 4h 25% v/v RAC (7) 4h 
12.5% v/v HS (8) 4h 25% v/v HS (9) 24h Ctrl (10) 24h 1 μM Staurosporine (11) 
24h 5 mM NaB (12) 24h 12.5% v/v combined herbs (13) 24h 25% v/v combined 
herbs (14) 24h 12.5% v/v RAC (15) 24h 25% v/v RAC (16) 24h 12.5% v/v HS (17) 
24h 25% v/v HS (18) 24h 25% v/v PA. The arrow indicates DNA fragmentation 
observed when the cells undergo apoptosis.
1 2   3   4   5   6   7   8      9 10 11 12 13 14 15 16 17  18
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Combined herbs had a general protective effect in the prevention of necrosis in all 
four colonic cell lines (Fig 4.86-Fig 4.93). Most herbs previously shown to increase 
cell death by apoptosis did not cause an increase in level of lactate dehydrogenase 
measured. No significant necrosis was measured in all four cell lines which could 
possibly indicate that the herbs do not work by necrosis as a mode of cell death.
4.4.2 Lactate Dehydrogenase assay (Necrosis)















































Fig 4.86 Effect of 4h herbal extract treatment on HCT-116 cells.
Each value is represented as mean ± SD (n=4)
Results
93









































































Fig 4.87 Effect of 24h herbal extract treatment on HCT-116 cells.
Each value is represented as mean ± SD (n=4)

























































Fig 4.88 Effect of 4h herbal extract treatment on CaCO-2 cells.
Each value is represented as mean ± SD (n=4)
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Fig 4.89 Effect of 24h herbal extract treatment on CaCO-2 cells.
Each value is represented as mean ± SD (n=4)
































Fig 4.90 Effect of 4h herbal extract treatment on HT-29 cells.
Each value is represented as mean ± SD (n=4)
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Fig 4.91 Effect of 24h herbal extract treatment on HT-29 cells.
Each value is represented as mean ± SD (n=4)





















































Fig 4.92 Effect of 4h herbal extract treatment on CRL-1790 cells.
Each value is represented as mean ± SD (n=4)
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Fig 4.93 Effect of 24h herbal extract treatment on CRL-1790 cells.




5.1 Treatment of human colonic cells with herbal extract
The human colonic epithelium is a tissue with a high cell turnover rate, and loss of 
homeostasis lead to increase cell proliferation and/ or reduction in cell death 
allowing tumor cells growth (Barret 1991). The majority of colon cancers arise on a 
background of the adenomatous polyps by progressive accumulation of genetic 
abnormalities. The human colonic cells used in this study include HCT-116,
CaCO-2, HT-29 and CRL-1790, representative of the various stages of colon cancer. 
HCT-116 cells is representative of the carcinoma (late) stages, while CaCO-2 and 
HT-29 are representative of the adenocarcinoma stages of colon cancer and 
CRL-1790 is representative of the normal colon cells. The difference between 
CaCO-2 and HT-29 lies on their p53 status where CaCO-2 has p53 truncation while 
HT-29 has a p53 point mutation of a CGT to CAT mutation in codon 273 of exon 8.
The herbal concoction used in this study is claimed to possess anti-tumor clinical 
effect. Four hours incubation period was chosen to be representative of the direct 
effect of herbal extract on the human colonic cells while a 24 hours incubation 
period is representative of the systemic effect of the herbal extract on colonic cells. 
Oral consumption of the herbal extracts allows slow and gradual release of the 
active ingredients into the bloodstream. The slow and steady release of active 




5.2 Increased cell death observed in combined herbal extract-treated human 
colonic cells
To examine the mechanism that might account for the effects of combined herbs in 
the colonic cells, their effects on cell cycle distribution was first investigated. Flow 
cytometry with propidium iodide staining was used in the quantitative analysis of 
time and dosage dependent treatment of combined herbal extract on the four human 
colonic cells. This method allows us to determine the cellular responses of the 
colonic cells to the herbal extract given with regards to cell cycle arrest and cell 
death, therefore providing us with important information on the molecular 
mechanisms of the herbs cytotoxicity and sensitivity of the different colonic cells. 
In this experiment, it was shown that all four colonic cells showed increase cell 
death with accumulation of colonic cells in the sub-G1 phase of the cell cycle with 
respect to the control (Fig 4.1-4.8). A significant accumulation of HT-29 cells in the 
G2-M phase of the cell cycle occurred with a concomitant decrease of cells in the 
G1 phase when treated with 12.5% v/v combined herbal extract at 24 hours 
post-treatment. The G2-M cell cycle arrest is followed by an increment of cell death 
at 24 hours post treatment when a higher concentration of combined herbal extract 
was used (Fig 4.6). These findings suggest that combined herbs have a marked 
effect on HT-29 cells proliferation due to cell cycle arrest and cell death.
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Highest level of cell death was measured when normal colonic cell, CRL-1790, was 
treated with combined herbs showing an increment of 37% cell death in contrast to 
15%, 25% and 24% increment observed in HCT-29, CaCO-2 and HT-29 cells 
respectively. It would be most ideal for the herbal extract to work specifically on the 
cancer cells especially cancer of the later stages. Chemotherapy and radiotherapy 
are non cancer specific. 
Since the combined herbs were shown to have some killing effect on the colonic 
cells, we are interested to find out how the individual herbs in the herbal formula 
work on the four colonic cells.
5.3 Treatment of human colonic cells with individual herbal extract
As shown in Fig 4.1-Fig 4.8, the most significant amount of cell death was observed 
when the colonic cells were treated with 12.5% v/v and 25% v/v combined herbal 
extract. Therefore, individual herbal extract at these two concentrations were then 
used to test on all four colonic cells. Cell cycle analysis was performed as per that 
of the combined herbal extract to determine the effect of the individual herbal 
extract on the four colonic cells.
It was shown that the ten herbs have different death inducing effects on the four 
colonic cell lines with varying sensitivities. Most significant increase in cell death 
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was observed in HCT-116 cell when treated with HS and RAC with cell death 
increment of 12% and 15% respectively (Fig 4.16 and Fig 4.18). The increment in 
HCT-116 cell death of 12% and 15% when treated by HS and RAC individually is 
similar to that of the 15% cell death increment (Fig 4.2) when HCT-116 cells was 
treated with combined herbal extract. When a combination of HS and RAC was 
used to treat HCT-116, an increment of 50% cell death was measured (Fig 4.19). 
The interactions between the two herbs produced a synergistic effect when 
HCT-116 was treated with a combination of HS and RAC. Some interactions 
between the various herbs of the combined herbal extract could have reduced the 
efficacy of the two herbs. The synergistic effect observed could be due to the fact 
that these two herbs are commonly used in the treatment of tumor and inflammation. 
The combination of these two herbs could prove to be useful as they have a higher 
killing efficacy as compared to the combination of the ten herbs. GG commonly 
used in the detoxification of the body showed increased cell death in GG-treated 
HCT-116 cells but to a much lesser degree (Fig 4.13). LL used in the elimination of 
“heat” from the body interferes with the cell proliferation of HCT-116 resulting in 
cell cycle arrest at the G1 phase (Fig 4.14).
HS was shown to result in increased cell death in all four cell lines but to varying 
extent with the most significant increase in HCT-116 cells (Fig 4.16). HS worked 
differently on the different cell lines where HS also led to increase cell death 
measured in HS-treated CaCO-2 (Fig 4.27) and CRL-1790 (Fig 4.47). In the case of 
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HT-29 cells, HS induced cell arrest at the G2-M phase with a corresponding drop in 
the G1 phase, followed by a slight increase in cell death with increasing HS
concentration (Fig 4.37).
A slight increase in cell death was observed in CaCO-2 cells after treatment with the 
ten individual herbs (Fig 4.20-Fig 4.29). A more significant increase was only 
observed in HS and CR-treated CaCO-2 cells (Fig 4.27 and Fig 4.28). The 
combinatorial effects exerted on CaCO-2 cells by the ten individual herbs 
correspond to similar level of cell death measured in combined herbs-treated 
CaCO-2 cells. This could indicate that the herbal extract work in an additive manner 
on CaCO-2 cells. HT-29 and CRL-1790 cells on the other hand require the 
combinatorial interactions among the various herbs to achieve increased cell death.
Significant cell cycle arrest in the G2-M phase was observed in HT-29 cells when 
treated with the three out of the ten individual herbs. RA, GG and HS were shown 
to induce G2 arrest indicating that the cells is capable of arresting damaged cell 
from further cell proliferation even though HT-29 cells have a mutation in the p53
gene. p53 is involved in the induction of cell cycle arrest and apoptosis of DNA 
damage cells.
5.4 Immunomodulatory effects of the herbal extract on the human colonic cells
IL-4 was not produced by any of the human colonic cells used. Concentration of 
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IL-4 was shown to peak between 1.56% to 3.125% v/v combined herbs treatment
after which the level of IL-4 drop drastically. IL-4 has been associated with 
improved survival rates (Barth 1996) and was shown to inhibit the growth of many 
carcinoma cell types, including those of colorectal origins (Toi 1992; Lahm 1994; 
Topp 1995).
IL-10 is not constitutively produced in HCT-116 and CaCO-2 cells. However, levels 
of IL-10 were shown to increase in HCT-116 and CaCO-2 cells with increasing 
concentration of combined herbs, which would in turn down-regulate cell-mediated 
immunity (Th1 response). It was previously demonstrated that Th2-associated 
cytokines including IL-4 and IL-10, both of which are generally known to be 
anti-inflammatory cytokines, and potent inhibitors of Th1-type immune responses 
by suppressing the functions of T lymphocytes and macrophages (Racke 1994; 
Mueller 1996; Mueller 1997; Cameron 1997; Scott 1994; Maron 1999). Ability of 
the Th2-associated cytokines to inhibit the development of deleterious 
Th1-mediated immune responses suggested that they may be useful therapeutics for 
ablating certain autoimmune diseases (Racke 1994; Rocken 1996).
IL-8, an inflammatory cytokine was shown to increase in the cell supernatant with 
increasing period of incubation. Treatment of the human colonic cells with 
combined herbal extract caused a drop in the level of IL-8 measured with increasing 
herbal concentration in corresponding to increase in IL-4 and IL-10 concentrations. 
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This could indicate that the combined herbs formula generally has 
anti-inflammatory effect which is useful if taken over long term period as it was 
previously shown that continuous inflammatory conditions have been recognized as 
risk factors for a variety of human cancers (Lin 2001).
Some levels of TGF-β1 were measured in all four colonic cells without any 
treatment. Activity of TGF-β1 was totally suppressed when treated with combined 
herbal extract which indicates that the combined herbs might be able to help in the 
inhibition of colon carcinoma progression to metastasis.
IL-10 is shown to be necessary as a secondary factor to facilitate TGF-β1 
production. IL-10 is required to down-regulate the ambient levels of Th1 cytokine, 
which would otherwise inhibit the expansion of TGF-β1 producing T cells (Fuss 
2002). However, such a trend was not observed in HCT-116 and CaCO-2 cells 
where IL-10 production was up-regulated when treated with combined herbal 
treatment while TGF-β1 production was down-regulated. This is probably due to the 
absence of TGF-β1 producing T-cells in our in-vitro monoculture system.
We are also interested to find out what cytokines are up-regulated as well as 
suppressed in individual herbal treatment that showed increased cell death in the 
colonic cells tested. Similar trends to the combined herbal treatment were observed 
in HS and RAC treated- HCT-116 cells. GG on the other hand caused a significant 
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up-regulation of IL-8 production with no up-regulation of IL-4 and IL-10 
production. It could be implicated that during the application of the herbs, the body 
inflammatory response was up-regulated, which in turn stimulate the activity of 
macrophages. 
CR which is commonly used to stimulate blood flow to prevent blood stagnancy 
was shown to stimulate IL-8 production in both CaCO-2 and HT-29 cells while HS 
was shown to cause a down-regulation in the amount of IL-10 and simultaneously 
TGF-β1 production in both HT-29 and CRL-1790 cells. Different herbs were shown 
to act differently on the different colonic cells; even the same herbs may lead to 
different cytokines regulation.
5.5 Mechanism of cell death induced by the herbal extract
Apoptosis and necrosis was previously described to be the two main forms of 
eukaryotic cell death (Kerr 1994). As described in section 5.2 and 5.3, increased cell 
death was observed in the human colonic cells when treated with combined herbs 
treatment as well as some individual herbs. As the increased cell death in herbal 
extract-treated human colonic cells could be due to either apoptosis or necrosis, 
therefore, DNA laddering assay for detection of apoptosis and lactate 
dehydrogenase assay for detection of necrosis were performed to identify the mode 
of action of the herbal extract on the colonic cells.
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Apoptosis is an active process whereby cells undergo a systematic, genetically 
controlled internal program of self-destruction.  It occurs in response to a wide 
variety of stimuli and normally occurs at a late, irreversible stage of cellular injury. 
Apoptosis selectively removes the most heavily damaged cells from tissues and 
apoptotic cells exhibit hallmark characteristics such as DNA fragmentation (Wyllie 
1980). Staurosporine, a potent apoptogenic agent was previously shown to be an 
effective inducer of apoptosis when used at a concentration of 1 μM. Addition of 
staurosporine for 24 hours was shown to increase Annexin-PI staining up to 90-95% 
by inducing apoptosis via both caspase-dependent as well as caspase-independent 
pathways in tumor cells that are normally resistant to chemotherapeutic drugs 
(Stepczynska 2001; Belmokhtar 2001; Joseph B 2002). The second apoptotic 
inducer used is sodium butyrate which was shown to be able to induce cell cycle 
arrest, differentiation as well as apoptosis in various cancer cells (Cummings 1997). 
Incubation of HCT-116 cells with 5 mM of sodium butyrate was shown by 
Bossenmeyer-Pourie (2002) to induce apoptosis. Therefore, 1 μM of staurosporine 
and 5 mM of sodium butyrate were used as the positive control in the induction of 
apoptosis in the DNA laddering assay.
The apoptotic DNA laddering kit was used to demonstrate the fragmentation of 
DNA which is the hallmark of apoptotic cells. As shown in figure 4.82, DNA 
smearing indicative of DNA degradation was observed in combined herbal 
extract-treated HCT-116, HT-29 and CRL-1790 cells. Apoptotic DNA laddering was 
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observed in combined herbs-treated CaCO-2 cells. Therefore, combined herbs 
treatment were shown to induce apoptosis in all 4 human colonic cells with greater 
effect observed in HCT-116, HT-29 and CRl-1790 cells as compared to CaCO-2 
cells in agreement with the flow cytometry study. RAC which was shown to cause a 
15% increment in cell death of HCT-116 as measured by flow cytometry (Fig 4.18) 
did not show a corresponding increment as significant as HS in the DNA laddering 
assay (Fig 4.82). Only slight DNA laddering was observed in RAC-treated 
HCT-116 cells. Laddering was also observed in GG-treated HCT-116 as indicated 
by the additional band observed in Lane 17 in Fig 4.82. CaCO-2 and HT-29 cells 
showed up-regulation of apoptosis when treated with HS and CR indicating that the 
increment in cell death as measured by flow cytometry is due to apoptosis (Fig 
4.83- 4.84). On the other hand, no visible DNA laddering was observed in 
CRL-1790 cells when treated with RAC, HS and PA (Fig 4.85) indicating that the 
cell death measured by flow cytometry is not due to apoptosis or it could also be 
possible that the amount of cell death was not high enough to be detected. 
Cytotoxicity assay with the measurement of the amount of lactate dehydrogenase 
(LDH) which is released during lysis of mammalian cells indicative of necrosis was 
used. Sodium chloride when used at a concentration of 0.5 M as previously reported 
by Koyama (2000) to induce cell death by osmotic pressure. It was also shown that 
usage of 0.5 M of sodium butyrate lead to extensive cell necrosis (Conway 1995).
The cytotoxicity of combined as well as individual herbal extracts on the human 
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colonic cells HCT-116, CaCO-2. HT-29 and CRL-1790 were tested, but no 
significant increased in amount of LDH were measured across varying herbal 
concentration and incubation period as compared to the negative control. 
Interestingly, a drop in the LDH level was measured which indicated that the 
increased cell death that was measured by flow cytometry was not caused by 
necrosis. The drop in LDH level lower than the control could also indicates that the 
herbal treatment may have an anti-inflammatory effect by preventing the induction 
of necrosis. This result is in conjunction to the IL-8 level measured where a 
decreased of IL-8 was generally measured. No necrosis was measured even at the 
maximal concentration used could possibly indicate that the herbal extract would 
not kill cells leading to inflammation of the tissue.
Apoptosis is a goal of cancer therapy but most cancers do not easily undergo 
apoptosis and are therefore resistant to chemotherapy (Martin 1994; Houghton 1999; 
Sellers 1999; Spierings 2003). Necrosis on the other hand is not an alternative to 
apoptosis as a higher dosage of cytotoxic agent would be required and would also 
lead to inflammatory responses. 
5.6 Conclusion
The usage of Traditional Chinese Medicine is gaining popularity worldwide serving 
as both an alternative as well as a complementary medicine to the synthetic drugs. 
More people are turning towards the use of herbal products and thus it is of interest 
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to find out the effectiveness as well as mechanism of the herbal compounds. 
It was shown that the combined herbal extract lead to increased cell death in the 
human colonic cells tested. Enhanced cell death was also observed in some 
individual herbal treatments. Synergistic effect was observed in HCT-116 cells 
when treated with a combination of RAC and HS while combinatorial effect exerted 
by the individual herbs on CaCO-2 correspond to the amount of cell death observed 
when treated with combined herbs. CRL-1790 and HT-29 showed little or no effect 
when treated with individual herbs which could possibly indicate that the herbs 
could only exert its effect via some chemical interactions between the various herbs. 
It was also shown that the increased cell death was caused by apoptosis and 
targeting apoptosis has always been a promising strategy for cancer drug discovery.
Some herbs when used individually do not exert a similar cytokine profile as that 
when they are in a concoction. A general trend of IL-4 and IL-10 up-regulation was 
observed with a corresponding down-regulation of IL-8 and TGF-β1 levels in most 
of the cells treated with the herbal extract.
In conclusion, individual and herbal concoction showed different effect on the 
normal and cancer cells. Cells of different phases in colon cancer have differing 
responses to the various herbs tested giving an indication of the potential of the 
therapeutic effects exerted by the herbs. More prominent effects of individual herbal 
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treatment were observed in colon cells of a later stage, which could be beneficial for 
colon cancer patients in the later stages of cancer without significant disruption of 
the normal colon cells. 
5.7 Future works
Future works that could be done include the mapping of apoptotic pathways with 
the use of caspase kit or western blot for herbal treatments that showed apoptotic 
cell death. Some studies have previously shown that treatment using 
chemotherapeutic drugs would activate death receptors in turn activating the 
caspase-8 pathway, leading to induction of cell death (Barnhart 2003). Caspases 
play an important role in the transduction of apoptotic signal after being processed 
into active forms in apoptotic cells and caspase-3 is considered to be a major 
execution caspase (Woo 1998; Porter 1999).
Animal model could be use to determine whether the similar effect is observed as 
compared to in vitro studies. Multiple intestinal neoplasia (Min) mice with APC 
mutation (ApcMin) could be used (Chen 2001). Apcmin is a murine model where 
multiple tumors would develop throughout the gastrointestinal tract within a few 
weeks after birth and is useful to observe the effect of the herbal extract to both the 
sporadic and inherited forms of colon cancer. Such mice are useful where they do 
not require exogenous carcinogens in the development of tumors and therefore 
lesser animals would be required to obtain statistical significant data. Tumors would 
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also be developed in the early stages of the mice’s lives and therefore experiments 
can be performed in a shorter timeframe.
Genetic sequencing to identify the genetic bases for the development of drugs 
resistant could be performed by comparing the DNA, RNA as well as proteins 
secreted in both resistant and sensitive cells. Optimum herbal dosages used could be 
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                                                       Appendix A
Appendix A
Phosphate Buffer Saline (1X)
Potassium di-Hydrogen phosphate 0.24 g/l
di-sodium hydrogen phosphate 1.44 g/l
Sodium chloride 8 g/l
Potassium chloride 0.2 g/l
Adjust to pH 7.4
Propidium Iodide
Propidium Iodide 1 mg
Phosphate Buffer Saline 1 ml
10 mM Tris-HCl buffer
Tris-HCl 1.576 g/l
Sodium chloride 0.877 g/l
Adjust to pH 7.5
1000 U/ml RNase A
RNase A 0.012 g
10 mM Tris-HCl buffer 1 ml 
                                                       Appendix A
FACS buffer
Glucose 1 g
Phosphate Buffer Saline 1 litre
Cell lysis solution
Hepes 0.024 g/ml
Sodium chloride 0.009 g/ml
Magnesium chloride 0.010 g/ml
0.5 M EDTA solution
Ethylenediaminetetraacetic acid 18.6 g/100 ml 
Adjust to pH 8.0 ± 0.1
TBE-buffer
Tris 5.4 g/l
Boric acid 2.8 g/l
0.5M EDTA solution 2 ml/l
Adjust to pH 8.0 ± 0.1
                                                       Appendix A
Loading dye (10X)
Sodium dodecyl sulfate 0.1 g
Bromophenol blue 25 mg
Glycerol 3 ml
Distilled water 7 ml
